Pfizer (PFE) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 28, 2020	Aug. 03, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 28, 2020
Document Transition Report	false
Entity File Number	1-3619
Entity Registrant Name	PFIZER INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-5315170
Entity Address, Address Line One	235 East 42nd Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	733-2323
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,556,879,807
Entity Central Index Key	0000078003
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, $.05 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $.05 par value
Trading Symbol	PFE
Security Exchange Name	NYSE
0.250% Notes due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes due 2022
Trading Symbol	PFE22
Security Exchange Name	NYSE
1.000% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2027
Trading Symbol	PFE27
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Costs and expenses:
Cost of sales	[1],[2]	2,281	2,576	4,658	5,009
Selling, informational and administrative expenses	[1],[2]	3,030	3,511	5,903	6,850
Research and development expenses	[1],[2]	2,132	1,842	3,856	3,544
Amortization of intangible assets	[1]	905	1,184	1,790	2,367
Restructuring charges and certain acquisition-related costs	[1]	362	(115)	431	(69)
(Gain) on completion of Consumer Healthcare JV transaction	[1]	0	0	(6)	0
Other (income)/deductions––net	[1]	(862)	126	(641)	218
Income from continuing operations before provision/(benefit) for taxes on income	[1],[3]	3,953	4,141	7,838	8,463
Provision/(benefit) for taxes on income	[1]	519	(915)	993	(481)
Income from continuing operations	[1]	3,434	5,056	6,845	8,945
Discontinued operations––net of tax	[1]	0	0	0	0
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,434	5,056	6,845	8,945
Less: Net income attributable to noncontrolling interests	[1]	8	10	17	15
Net income attributable to Pfizer Inc.	[1]	$ 3,426	$ 5,046	$ 6,828	$ 8,929
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.62	$ 0.91	$ 1.23	$ 1.59
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.62	0.91	1.23	1.59
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.89	1.22	1.56
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.89	$ 1.22	$ 1.56
Weighted-average shares––basic	[1]	5,554	5,562	5,550	5,598
Weighted-average shares––diluted	[1]	5,619	5,672	5,616	5,711
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019 , and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020		Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,434	$ 5,056	$ 6,845		$ 8,945
Foreign currency translation adjustments, net	[1],[5]	(242)	(485)	(1,513)		(161)
Reclassification adjustments	[1]	0	0	0	[5]	2	[5]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[1]	(242)	(485)	(1,513)		(159)
Unrealized holding gains/(losses) on derivative financial instruments, net	[1]	213	(176)	(288)		91
Reclassification adjustments for gains included in net income	[1],[6]	(186)	(81)	(167)		(343)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[1]	27	(256)	(455)		(252)
Unrealized holding gains/(losses) on available-for-sale securities, net	[1]	42	(7)	(9)		33
Reclassification adjustments for losses included in net income	[1],[7]	44	26	59		37
Other comprehensive income (loss), available-for-sale securities, before tax, total	[1]	87	19	50		70
Benefit plans: actuarial gains/(losses), net	[1]	5	(4)	(160)		(4)
Reclassification adjustments related to amortization	[1]	67	60	133		121
Reclassification adjustments related to settlements, net	[1]	13	2	66		2
Other	[1]	68	41	84		18
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[1]	153	100	122		137
Benefit plans: prior service costs and other, net	[1]	0	(1)	0		(1)
Reclassification adjustments related to amortization of prior service costs and other, net	[1]	(45)	(46)	(89)		(93)
Other	[1]	5	1	4		2
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[1]	(40)	(46)	(85)		(92)
Other comprehensive loss, before tax	[1]	(14)	(669)	(1,882)		(296)
Tax provision/(benefit) on other comprehensive loss	[1]	113	(59)	(265)		(34)
Other comprehensive loss before allocation to noncontrolling interests	[1],[3]	(127)	(610)	(1,617)		(262)
Comprehensive income before allocation to noncontrolling interests	[1]	3,307	4,446	5,227		8,683
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[1]	(4)	12	5		13
Comprehensive income attributable to Pfizer Inc.	[1]	$ 3,312	$ 4,434	$ 5,222		$ 8,669
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Amounts in the second quarter of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a gain of approximately $380 million pre-tax ( $291 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in the first six months of 2020 include a loss of approximately $1.2 billion pre-tax ( $902 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see Note 2B . Acquisition, Equity-Method Investment and Licensing Arrangements : Equity-Method Investment .
[6]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales , see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[7]	Reclassified into Other (income)/deductions—net.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[1]	$ (242)	$ (1,513)
GSK Consumer Healthcare [Member]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax		380	(1,200)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax		$ 291	$ (902)
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	[1]	$ 1,801	$ 1,305	[2]
Short-term investments	[1]	9,581	8,525
Restricted short-term investments	[1],[3]	11,412	0
Trade accounts receivable, less allowance for doubtful accounts: 2020—$525; 2019—$527	[1]	9,128	8,724
Inventories	[1],[4]	8,564	8,283
Current tax assets	[1]	3,426	3,344
Other current assets	[1]	2,513	2,622
Total current assets	[1]	46,424	32,803
Equity-method investments	[1]	15,578	17,133
Long-term investments	[1]	3,142	3,014
Property, plant and equipment, less accumulated depreciation: 2020—$16,889; 2019—$16,789	[1]	14,113	13,967
Identifiable intangible assets, less accumulated amortization	[1],[5]	33,541	35,370
Goodwill	[1]	58,449	58,653
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	2,360	2,099
Other noncurrent assets	[1]	4,327	4,450
Total assets	[1]	177,934	167,489
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020—$1,481; 2019—$1,462	[1]	13,084	16,195
Trade accounts payable	[1]	3,872	4,220
Dividends payable	[1]	2,111	2,104
Income taxes payable	[1]	1,445	980
Accrued compensation and related items	[1]	2,042	2,720
Other current liabilities	[1]	10,168	11,083
Total current liabilities	[1]	32,723	37,304
Long-term debt	[1],[3]	50,529	35,955
Pension benefit obligations, net	[1]	5,344	5,638
Postretirement benefit obligations, net	[1]	1,086	1,124
Noncurrent deferred tax liabilities	[1]	5,409	5,578
Other taxes payable	[1]	11,468	12,126
Other noncurrent liabilities	[1]	6,812	6,317
Total liabilities	[1]	113,370	104,042
Commitments and Contingencies	[1]
Preferred stock	[1]	0	17
Common stock	[1]	470	468
Additional paid-in capital	[1]	87,886	87,428
Treasury stock	[1]	(110,978)	(110,801)
Retained earnings	[1]	100,203	97,670
Accumulated other comprehensive loss	[1]	(13,246)	(11,640)
Total Pfizer Inc. shareholders’ equity	[1]	64,336	63,143
Equity attributable to noncontrolling interests	[1]	228	303
Total equity	[1],[6]	64,564	63,447
Total liabilities and equity	[1]	$ 177,934	$ 167,489
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see Note 7D. Financial Instruments: Long-Term Debt
[4]	The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.
[5]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 525	$ 527
Property, plant and equipment, accumulated depreciation	[1]	16,889	16,789
Current portion of long-term debt	[1]	$ 1,481	$ 1,462
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total		Preferred Stock [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Shareholders' Equity [Member]	Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2018	[1]			478	9,332,000,000		3,615,000,000
Beginning balance at Dec. 31, 2018	[1]	$ 63,758		$ 19	$ 467	$ 86,253	$ (101,610)	$ 89,554	$ (11,275)	$ 63,407	$ 351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	8,945	[2],[3],[4]					8,929		8,929	15
Other comprehensive income/(loss), net of tax	[1]	(262)	[2]						(260)	(260)	(2)
Cash dividends declared:
Common stock	[1]	(4,062)						(4,062)		(4,062)
Preferred stock	[1]	(1)						(1)		(1)
Noncontrolling interests	[1]	(8)									(8)
Share-based payment transactions (in shares)	[1]				31,000,000		7,000,000
Share-based payment transactions	[1]	402			$ 2	712	$ (312)			402
Purchases of common stock (in shares)	[1]						(180,000,000)
Purchases of common stock	[1]	(8,865)					$ (8,865)			(8,865)
Preferred stock conversions and redemptions (in shares)	[1]			(20)
Preferred stock conversions and redemptions	[1]	(2)		$ (1)		(1)				(2)
Other	[1],[5]	19						19		19
Ending balance (in shares) at Jun. 30, 2019	[1]			458	9,363,000,000		3,801,000,000
Ending balance at Jun. 30, 2019	[1]	59,924		$ 18	$ 468	86,963	$ (110,786)	94,440	(11,535)	59,568	357
Beginning balance (in shares) at Mar. 31, 2019	[1]			466	9,358,000,000		3,801,000,000
Beginning balance at Mar. 31, 2019	[1]	59,158		$ 19	$ 468	86,635	$ (110,781)	93,388	(10,923)	58,806	352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	5,056	[2],[3],[4]					5,046		5,046	10
Other comprehensive income/(loss), net of tax	[1]	(610)	[2]						(613)	(613)	3
Cash dividends declared:
Common stock	[1]	(3,994)						(3,994)		(3,994)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(8)									(8)
Share-based payment transactions (in shares)	[1]				5,000,000
Share-based payment transactions	[1]	324			$ 0	329	$ (6)			324
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0			0
Preferred stock conversions and redemptions (in shares)	[1]			(8)
Preferred stock conversions and redemptions	[1]	(1)		$ 0		(1)				(1)
Other	[1]	0						0		0
Ending balance (in shares) at Jun. 30, 2019	[1]			458	9,363,000,000		3,801,000,000
Ending balance at Jun. 30, 2019	[1]	59,924		$ 18	$ 468	86,963	$ (110,786)	94,440	(11,535)	59,568	357
Beginning balance (in shares) at Dec. 31, 2019	[1]			431	9,369,000,000		3,835,000,000
Beginning balance at Dec. 31, 2019	[1]	63,447	[6]	$ 17	$ 468	87,428	$ (110,801)	97,670	(11,640)	63,143	303
Beginning balance (in shares) at Dec. 31, 2019	[1]			431	9,369,000,000		3,835,000,000
Beginning balance at Dec. 31, 2019	[1]	63,447	[6]	$ 17	$ 468	87,428	$ (110,801)	97,670	(11,640)	63,143	303
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	6,845	[2],[3],[4]					6,828		6,828	17
Other comprehensive income/(loss), net of tax	[1]	(1,617)	[2]						(1,605)	(1,605)	(12)
Cash dividends declared:
Common stock	[1]	(4,294)						(4,294)		(4,294)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(80)									(80)
Share-based payment transactions (in shares)	[1]				25,000,000		6,000,000
Share-based payment transactions	[1]	266			$ 1	473	$ (208)			266
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0
Preferred stock conversions and redemptions (in shares)	[1],[7]			(431)			(1,000,000)
Preferred stock conversions and redemptions	[1],[7]	(1)		$ (17)		(15)	$ 31			(1)
Other (in shares)	[1]						0
Other	[1]	0				0		0		0	0
Ending balance (in shares) at Jun. 28, 2020	[1]			0	9,394,000,000		3,840,000,000
Ending balance at Jun. 28, 2020	[1]	64,564	[6]	$ 0	$ 470	87,886	$ (110,978)	100,203	(13,246)	64,336	228
Beginning balance (in shares) at Mar. 29, 2020	[1]			417	9,393,000,000		3,841,000,000
Beginning balance at Mar. 29, 2020	[1]	65,338		$ 17	$ 470	87,680	$ (111,010)	101,000	(13,131)	65,026	312
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,434	[2],[3],[4]					3,426		3,426	8
Other comprehensive income/(loss), net of tax	[1]	(127)	[2]						(115)	(115)	(12)
Cash dividends declared:
Common stock	[1]	(4,223)						(4,223)		(4,223)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(80)									(80)
Share-based payment transactions (in shares)	[1]				2,000,000		0
Share-based payment transactions	[1]	222			$ 0	221	$ 1			222
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0			0
Preferred stock conversions and redemptions (in shares)	[1],[7]			(417)			(1,000,000)
Preferred stock conversions and redemptions	[1],[7]	0		$ (17)		(14)	$ 31			0
Other	[1]	0						0		0	0
Ending balance (in shares) at Jun. 28, 2020	[1]			0	9,394,000,000		3,840,000,000
Ending balance at Jun. 28, 2020	[1]	$ 64,564	[6]	$ 0	$ 470	$ 87,886	$ (110,978)	$ 100,203	$ (13,246)	$ 64,336	$ 228
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	The increase to Retained earnings represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 in our 2019 Financial Report.
[6]	Amounts may not add due to rounding.
[7]	On May 4, 2020, all outstanding shares of Pfizer’s Series A convertible perpetual preferred stock were converted into shares of Pfizer common stock. See Note 11. Equity for additional information.

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 6,845	$ 8,945
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[2]	2,469	3,073
Asset write-offs and impairments	[2]	58	178
TCJA impact	[2],[5]	0	(285)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[2]	(6)	0
Deferred taxes from continuing operations	[2]	71	(160)
Share-based compensation expense	[2]	258	384
Benefit plan contributions in excess of expense/income	[2]	(418)	(313)
Other adjustments, net	[2]	(361)	(462)
Other changes in assets and liabilities, net of acquisitions and divestitures	[2]	(2,229)	(7,051)
Net cash provided by operating activities	[2]	6,688	4,309
Investing Activities
Purchases of property, plant and equipment	[2]	(942)	(939)
Purchases of short-term investments	[2]	(5,141)	(4,063)
Proceeds from redemptions/sales of short-term investments	[2]	4,595	6,001
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[2],[6]	(11,949)	4,717
Purchases of long-term investments	[2]	(168)	(123)
Proceeds from redemptions/sales of long-term investments	[2]	536	142
Acquisitions of intangible assets	[2]	(33)	(267)
Other investing activities, net	[2]	19	179
Net cash provided by/(used in) investing activities	[2]	(13,082)	5,648
Financing Activities
Proceeds from short-term borrowings	[2]	12,352	3,956
Principal payments on short-term borrowings	[2]	(13,166)	(2,375)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less	[2]	(2,273)	2,719
Proceeds from issuance of long-term debt	[2],[6]	16,606	4,942
Principal payments on long-term debt	[2]	(2,181)	(5,355)
Purchases of common stock	[2]	0	(8,865)
Cash dividends paid	[2]	(4,216)	(4,047)
Proceeds from exercise of stock options	[2]	158	248
Other financing activities, net	[2]	(321)	(541)
Net cash provided by/(used in) financing activities	[2]	6,959	(9,318)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[2]	(70)	(28)
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[2]	495	612
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[2]	1,350	1,225
Cash and cash equivalents and restricted cash and cash equivalents, end	[2]	1,845	1,837
Cash paid (received) during the period for:
Income taxes	[2]	1,290	2,136
Interest paid	[2]	910	809
Interest rate hedges	[2]	$ (66)	$ (72)
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income for the six months ended June 30, 2019 was favorably impacted by approximately $285 million , primarily as a result of additional guidance issued by the U.S. Department of Treasury.
[6]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020	Jun. 30, 2019
TCJA impact	[1],[2]		$ 0	$ (285)
Proceeds from issuance of long-term debt	[1],[3]		16,606	$ 4,942
Subsidiaries [Member] | Upjohn Inc [Member]
Proceeds from issuance of long-term debt		$ 11,400	$ 11,400
[1]	Amounts may not add due to rounding.
[2]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income for the six months ended June 30, 2019 was favorably impacted by approximately $285 million , primarily as a result of additional guidance issued by the U.S. Department of Treasury.
[3]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 24, 2020 and May 26, 2019 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended June 28, 2020 and June 30, 2019 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2019 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see Note 14 . Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements. For additional information, see Note 14. Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. For additional information, see Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, and Note 2 . Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. In the first quarter of 2020 , as of January 1, 2020 , we adopted four new accounting standards. See Note 1B for further information. B. Adoption of New Accounting Standards in 2020 On January 1, 2020 , we adopted four new accounting standards. Credit Losses on Financial Instruments ––We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer’s credit improves. We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of Retained earnings was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the three and six months ended June 28, 2020 or condensed consolidated statement of cash flows for the six months ended June 28, 2020 , nor on our condensed consolidated balance sheet as of June 28, 2020 . For additional information, see Note 1C . Goodwill Impairment Testing ––We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Implementation Costs in a Cloud Computing Arrangement ––We prospectively adopted the new standard related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements. Collaboration Agreements ––We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2019, we adopted four new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 included in our 2019 Financial Report. C. Revenues and Trade Accounts Receivable Deductions from Revenues–– Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.5 billion as of June 28, 2020 and $5.7 billion as of December 31, 2019 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) June 28, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,129 $ 1,257 Other current liabilities : Accrued rebates 3,210 3,285 Other accruals 576 581 Other noncurrent liabilities 598 565 Total accrued rebates and other accruals $ 5,512 $ 5,689 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. During the three and six months ended June 28, 2020 , additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.

Acquisition, Equity-Method Inve

Acquisition, Equity-Method Investment and Licensing Arrangements	6 Months Ended
	Jun. 28, 2020
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Acquisition, Equity-Method Investment and Licensing Arrangements	Acquisition, Equity-Method Investment and Licensing Arrangements A. Acquisition Array BioPharma Inc. On July 30, 2019 , we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ( $10.9 billion , net of cash acquired). Array’s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib). The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. B. Equity-Method Investment Formation of GSK Consumer Healthcare Joint Venture On July 31, 2019 , we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a 32% equity stake in the new company and GSK owns the remaining 68% . Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ( $5.4 billion , net of tax) in our fiscal third quarter of 2019 in (Gain) on completion of Consumer Healthcare JV transaction for the difference in the fair value of our 32% equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. Our financial results, and our Consumer Healthcare segment’s operating results, for the second quarter of 2019 reflect three months of Consumer Healthcare segment operations and for the first six months of 2019 reflect six months of Consumer Healthcare segment operations, while financial results for the second quarter and first six months of 2020 do not reflect any contribution from the Consumer Healthcare business. We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately $15.4 billion as of June 28, 2020 and $17.0 billion as of December 31, 2019 and is reported as a private equity investment in the Equity-method investments line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in Other (income)/deductions––net commencing from August 1, 2019. Therefore, we recorded our share of the joint venture’s earnings generated in the first quarter of 2020, which totaled approximately $129 million , in our operating results in the second quarter of 2020 . Our total share of the joint venture’s earnings generated in the fourth quarter of 2019 and the first quarter of 2020, which we recorded in our operating results for the first six months of 2020 , was approximately $140 million . See Note 4 . As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately $15.7 billion and that 32% of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately $11.2 billion , resulting in an initial basis difference of approximately $4.5 billion . In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in Other (income)/deductions––net commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our 32% share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately $11.0 billion and our initial basis difference was increased to approximately $4.8 billion . The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the first quarter of 2020 totaling approximately $4 million of expense is included in our operating results in Other (income)/deductions––net in the second quarter of 2020 . The total amortization of these basis differences for the fourth quarter of 2019 and the first quarter of 2020, which was included in our operating results in the first six months of 2020 , was approximately $48 million of expense. See Note 4. Amortization of basis differences on inventory and related deferred tax liabilities has been completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from 6 to 20 years . GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in Other comprehensive income . The decrease in the value of our investment from December 31, 2019 to June 28, 2020 is primarily due to approximately $1.1 billion in pre-tax foreign currency translation adjustments (see Note 6 ), as well as a dividend of approximately $519 million , which was received from the GSK Consumer Healthcare joint venture in June 2020. As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $274 million for the second quarter of 2019 and $554 million for the six months ended June 30, 2019 . Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows: (MILLIONS OF DOLLARS) March 31, Current assets $ 8,213 Noncurrent assets 37,627 Total assets $ 45,840 Current liabilities $ 5,524 Noncurrent liabilities 5,152 Total liabilities $ 10,677 Equity attributable to shareholders $ 35,031 Equity attributable to noncontrolling interests 133 Total net equity $ 35,163 (MILLIONS OF DOLLARS) Three Months Ended March 31, 2020 Six Months Ended March 31, 2020 Net sales $ 3,503 $ 6,691 Cost of sales (1,394 ) (3,205 ) Gross profit $ 2,109 $ 3,486 Income from continuing operations 425 471 Net income 425 471 Income attributable to shareholders 405 441 C. Licensing Arrangements Agreement with Valneva SE On April 30, 2020 , we signed an agreement to co-develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of $308 million in cash payments consisting of a $130 million upfront payment, which was paid and recorded in Research and development expenses in our fiscal second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization. Agreement with BioNTech SE On April 9, 2020 , we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&D, regulatory capabilities, and global manufacturing and distribution network. In connection with the agreement, we paid BioNTech an upfront cash payment of $72 million , which was recorded in Research and development expenses in our fiscal second quarter of 2020, and we made an equity investment of $113 million in common stock of BioNTech. BioNTech is eligible to receive potential future milestone payments of up to $563 million for a total consideration of $748 million . While Pfizer and BioNTech will share development costs equally if the vaccine is approved and successfully commercialized, Pfizer will be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its 50 percent share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd) if development is successful and regulatory approval is obtained. We made an additional investment of $50 million in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020 in our fiscal third quarter of 2020.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	6 Months Ended
	Jun. 28, 2020
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. Transforming to a More Focused Company Program With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines. As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&D, Manufacturing and Commercial. We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately $1.2 billion on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs. Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately $400 million , with approximately 20% of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. From the start of this program in the fourth quarter of 2019 through June 28, 2020 , we incurred approximately $549 million associated with this program. Current-Period Key Activities For the first six months of 2020 , we incurred costs of $566 million composed primarily of the Transforming to a More Focused Company program. For the first six months of 2019, we incurred costs of $32 million composed of $180 million associated with the 2017-2019 and Organizing for Growth initiatives, $51 million associated with the integration of Hospira, and income of $199 million primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Restructuring charges/(credits): Employee terminations $ 346 $ (166 ) $ 371 $ (167 ) Asset impairments (8 ) (9 ) 23 — Exit costs 1 31 1 34 Restructuring charges (a) 340 (144 ) 396 (134 ) Transaction costs (b) 11 — 14 — Integration costs and other (c) 11 29 21 64 Restructuring charges and certain acquisition-related costs 362 (115 ) 431 (69 ) Net periodic benefit costs recorded in Other (income)/deductions––net 5 4 29 10 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 4 7 10 15 Selling, informational and administrative expenses — 1 — 2 Research and development expenses 2 2 (3 ) 5 Total additional depreciation––asset restructuring 6 10 6 23 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 11 17 21 31 Selling, informational and administrative expenses 63 16 78 25 Research and development expenses 1 9 1 13 Total implementation costs 75 42 99 69 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 449 $ (59 ) $ 566 $ 32 (a) In the second quarter and first six months of 2020 , restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the second quarter and first six months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report. The restructuring activities for 2020 are associated with the following: • For the second quarter of 2020 , Biopharma ( $12 million credit); Upjohn ( $1 million credit); and Other ( $352 million charge). • For the first six months of 2020 , Biopharma ( $9 million credit); Upjohn ( $12 million charge); and Other ( $393 million charge). The restructuring activities for 2019 are associated with the following: • For the second quarter of 2019 , Biopharma ( $62 million credit); Upjohn ( $9 million credit); and Other ( $74 million credit). • For the first six months of 2019 , Biopharma ( $48 million credit); Upjohn ( $22 million credit); and Other ( $63 million credit). Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the second quarter and first six months of 2020 , restructuring costs identified as Other primarily relate to corporate enabling functions. (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the second quarter and first six months of 2020 , integration costs and other were mostly related to our acquisition of Array. In the second quarter and first six months of 2019 , integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2019 (a) $ 887 $ — $ 46 $ 933 Provision 371 23 1 396 Utilization and other (b) (341 ) (23 ) (14 ) (378 ) Balance, June 28, 2020 (c) $ 918 $ — $ 34 $ 951 (a) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $625 million ) and Other noncurrent liabilities ( $326 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	6 Months Ended
	Jun. 28, 2020
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Interest income (a) $ (19 ) $ (59 ) $ (53 ) $ (125 ) Interest expense (a) 372 389 762 750 Net interest expense 353 330 709 625 Royalty-related income (b) (191 ) (231 ) (311 ) (320 ) Net (gains)/losses on asset disposals 1 — 2 (1 ) Net gains recognized during the period on equity securities (c) (732 ) (36 ) (478 ) (147 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (d) (100 ) (22 ) (215 ) (104 ) Net periodic benefit credits other than service costs (e) (108 ) (51 ) (175 ) (91 ) Certain legal matters, net 17 15 26 19 Certain asset impairments (f) — 10 — 160 Business and legal entity alignment costs (g) — 137 — 256 Net losses on early retirement of debt — — — 138 GSK Consumer Healthcare JV equity method (income)/loss (h) (126 ) — (92 ) — Other, net (i) 25 (27 ) (107 ) (318 ) Other (income)/deductions––net $ (862 ) $ 126 $ (641 ) $ 218 (a) Interest income decreased in the second quarter and first six months of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the second quarter of 2020 mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of 2020 , mainly as a result of an increased commercial paper balance due to the acquisition of Array. (b) Royalty-related income for the second quarter and first six months of 2019 included a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million . (c) The gains in the second quarter of 2020 include, among other things, unrealized gains of $508 million related to our investment in Allogene and unrealized gains of $61 million related to our investment in BioNTech. The gains in the first six months of 2020 include, among other things, unrealized gains of $374 million related to our investment in Allogene and unrealized gains of $127 million related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of $104 million related to our investment in Cortexyme, Inc. For additional information on investments, see Note 7B . (d) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter and first six months of 2020 , mainly includes, among other things, $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first six months of 2020 also includes an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first six months of 2019 , primarily included $68 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® . (e) For additional information, see Note 10 . (f) The first six months of 2019 included intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development, (ii) $40 million related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) $10 million related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflected , among other things, updated commercial forecasts. In addition, the first six months of 2019 included other asset impairments of $20 million . (g) In the second quarter and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. (h) Includes our share of the GSK Consumer Healthcare joint venture’s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See Note 2B for additional information. (i) The second quarter of 2020 includes, among other things, dividend income of $76 million from our investment in ViiV, and charges of $86 million , reflecting the change in the fair value of contingent consideration. The first six months of 2020 includes, among other things, dividend income of $153 million from our investment in ViiV and charges of $99 million , reflecting the change in the fair value of contingent consideration. The second quarter of 2019 included, among other things, charges of $81 million , reflecting the change in the fair value of contingent consideration, dividend income of $76 million from our investment in ViiV, and $25 million of income from insurance recoveries related to Hurricane Maria. The first six months of 2019 included, among other things, dividend income of $140 million from our investment in ViiV and $50 million of income from insurance recoveries related to Hurricane Maria.

Tax Matters

Tax Matters	6 Months Ended
	Jun. 28, 2020
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 13.1% for the second quarter of 2020 , compared to (22.1)% for the second quarter of 2019 and was 12.7% for the first six months of 2020 , compared to (5.7)% for the first six months of 2019 . The higher effective tax rate for the second quarter and first six months of 2020 in comparison with the same periods in 2019 was primarily due to: • the non-recurrence of the $1.4 billion tax benefit, representing taxes and interest, recorded in the second quarter of 2019 due to the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report); and • the non-recurrence of the tax benefit recorded in the first six months of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA, partially offset by: • the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business. Our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current Income taxes payable (approximately $1.4 billion ) and the remaining liability is reported in noncurrent Other taxes payable in our condensed consolidated balance sheet as of June 28, 2020 . The second installment of $680 million was paid in July 2020, which was originally due to be paid in April 2020 but was extended to July 2020 by the IRS in response to the COVID-19 pandemic. The third installment of approximately $750 million is due in April 2021. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of June 28, 2020 , neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2011-2013. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2014-2015 are currently under audit. Tax years 2016-2020 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2020), Japan (2017-2020), Europe (2011-2020, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020). C. Tax Provision/(Benefit) on Other Comprehensive Loss The following table provides the components of Tax provision/(benefit) on other comprehensive loss : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Foreign currency translation adjustments, net (a) $ 60 $ (17 ) $ (192 ) $ 10 Unrealized holding gains/(losses) on derivative financial instruments, net 51 (53 ) (82 ) 6 Reclassification adjustments for gains included in net income (35 ) (4 ) (20 ) (59 ) 16 (57 ) (102 ) (53 ) Unrealized holding gains/(losses) on available-for-sale securities, net 5 (1 ) (1 ) 4 Reclassification adjustments for losses included in net income 6 3 7 5 11 2 6 9 Benefit plans: actuarial gains/(losses), net 2 (1 ) (19 ) (1 ) Reclassification adjustments related to amortization 16 15 31 18 Reclassification adjustments related to settlements, net 2 — 12 1 Other 16 8 20 3 35 23 43 21 Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) (21 ) (22 ) Other 1 — 1 — (9 ) (11 ) (20 ) (22 ) Tax provision/(benefit) on other comprehensive loss $ 113 $ (59 ) $ (265 ) $ (34 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2019 $ (5,952 ) $ 20 $ (35 ) $ (6,257 ) $ 584 $ (11,640 ) Other comprehensive income/(loss) (a) (1,310 ) (353 ) 44 79 (65 ) (1,605 ) Balance, June 28, 2020 $ (7,262 ) $ (333 ) $ 9 $ (6,178 ) $ 518 $ (13,246 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $12 million loss for the first six months of 2020. Includes after-tax losses of approximately $902 million related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), and losses from the weakening of certain major currencies against the U.S. dollar. These losses were partially offset by the results of our net investment hedging program.

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 28, 2020
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in our 2019 Financial Report: June 28, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds (a) $ 13,033 $ — $ 13,033 $ 705 $ — $ 705 Classified as available-for-sale debt securities: Government and agency—non-U.S. 6,218 — 6,218 4,863 — 4,863 Government and agency—U.S. 14 — 14 811 — 811 Corporate and other 1,440 — 1,440 1,013 — 1,013 7,672 — 7,672 6,687 — 6,687 Total short-term investments 20,705 — 20,705 7,392 — 7,392 Other current assets Derivative assets: Interest rate contracts 17 — 17 53 — 53 Foreign exchange contracts 413 — 413 413 — 413 Total other current assets 431 — 431 465 — 465 Long-term investments Classified as equity securities with readily determinable fair values (b) 2,072 2,046 26 1,902 1,863 39 Classified as available-for-sale debt securities: Government and agency—U.S. 243 — 243 303 — 303 Corporate and other 11 — 11 11 — 11 254 — 254 315 — 315 Total long-term investments 2,326 2,046 280 2,216 1,863 354 Other noncurrent assets Derivative assets: Interest rate contracts 140 — 140 266 — 266 Foreign exchange contracts 221 — 221 261 — 261 Total derivative assets 362 — 362 526 — 526 Insurance contracts (c) 578 — 578 575 — 575 Total other noncurrent assets 940 — 940 1,102 — 1,102 Total assets $ 24,402 $ 2,046 $ 22,355 $ 11,176 $ 1,863 $ 9,313 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 127 $ — $ 127 $ 114 $ — $ 114 Total other current liabilities 127 — 127 114 — 114 Other noncurrent liabilities Derivative liabilities: Foreign exchange contracts 866 — 866 604 — 604 Total other noncurrent liabilities 866 — 866 604 — 604 Total liabilities $ 993 $ — $ 993 $ 718 $ — $ 718 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. (b) As of June 28, 2020 , long-term equity securities of $163 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. (c) Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the condensed consolidated statements of income (see Note 4 ). Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: June 28, 2020 December 31, 2019 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion (a) $ 50,529 $ 59,121 $ 59,121 $ 35,955 $ 40,842 $ 40,842 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 28, 2020 or December 31, 2019 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach. In addition, as of June 28, 2020 and December 31, 2019 , we had long-term receivables whose fair value is based on Level 3 inputs. As of June 28, 2020 and December 31, 2019 , the differences between the estimated fair values and carrying values of these receivables were not significant. Total Short-Term and Long-Term Investments and Equity-Method Investments The following table represents our investments by classification type: (MILLIONS OF DOLLARS) June 28, December 31, Short-term investments Equity securities with readily determinable fair values (a) $ 13,033 $ 705 Available-for-sale debt securities 7,672 6,687 Held-to-maturity debt securities 288 1,133 Total Short-term investments $ 20,993 $ 8,525 Long-term investments Equity securities with readily determinable fair values $ 2,072 $ 1,902 Available-for-sale debt securities 254 315 Held-to-maturity debt securities 43 42 Private equity securities at cost 772 756 Total Long-term investments $ 3,142 $ 3,014 Equity-method investments 15,578 17,133 Total long-term investments and equity-method investments $ 18,720 $ 20,147 Held-to-maturity cash equivalents $ 119 $ 163 (a) As of June 28, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. . B. Investments Debt Securities At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: June 28, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 6,209 $ 12 $ (3 ) $ 6,218 $ 6,218 $ — $ — $ 6,218 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 257 1 (1 ) 257 14 243 — 257 1,120 — (6 ) 1,114 Corporate and other (a) 1,450 2 (1 ) 1,451 1,440 11 — 1,451 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 228 — — 228 189 9 30 228 535 — — 535 Government and agency –– non-U.S. 222 — — 222 218 — 4 222 803 — — 803 Total debt securities $ 8,366 $ 16 $ (5 ) $ 8,376 $ 8,079 $ 263 $ 35 $ 8,376 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations. For our portfolio of available-for-sale and held-to-maturity debt securities, any expected credit losses would be immaterial to the financial statements. Equity Securities The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Net gains recognized during the period on equity securities (a ) $ (732 ) $ (36 ) $ (478 ) $ (147 ) Less: Net (gains)/losses recognized during the period on equity securities sold during the period 1 (6 ) (18 ) (10 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date (b) $ (733 ) $ (31 ) $ (459 ) $ (137 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . (b) Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $67 million and upward adjustments of $66 million . Impairments, downward and upward adjustments were not significant in the second quarter and the first six months of 2020 and 2019 . C. Short-Term Borrowings Short-term borrowings include: (MILLIONS OF DOLLARS) June 28, December 31, Commercial paper $ 10,660 $ 13,915 Current portion of long-term debt, principal amount 1,481 1,458 Other short-term borrowings, principal amount (a) 956 860 Total short-term borrowings, principal amount 13,097 16,233 Net fair value adjustments related to hedging and purchase accounting 1 5 Net unamortized discounts, premiums and debt issuance costs (14 ) (43 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 13,084 $ 16,195 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E D. Long-Term Debt New Issuances In the second quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of June 28, 2020 Pfizer Inc. (a) 0.800% May 28, 2025 $ 750 1.700% May 28, 2030 1,000 2.550% May 28, 2040 1,000 2.700% May 28, 2050 1,250 $ 4,000 Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc. (b) 1.125% June 22, 2022 $ 1,000 1.650% June 22, 2025 750 2.300% June 22, 2027 750 2.700% June 22, 2030 1,450 3.850% June 22, 2040 1,500 4.000% June 22, 2050 2,000 $ 7,450 Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc. (b) 0.816% June 23, 2022 € 750 1.023% June 23, 2024 750 1.362% June 23, 2027 850 1.908% June 23, 2032 1,250 € 3,600 (a) The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was 2.11% . (b) In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were 2.95% for the $7.45 billion notes and 1.37% for the €3.60 billion notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to 101% of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer’s stockholders of all of the issued and outstanding shares of Upjohn Inc.’s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the $11.4 billion of proceeds are classified as Restricted short-term investments in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements. In the first quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of June 28, 2020 2.625% (a) April 1, 2030 $ 1,250 Total long-term debt issued in the first quarter of 2020 (b) $ 1,250 (a) The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest. (b) The effective interest rate for the notes at issuance was 2.67% . The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) June 28, December 31, Total long-term debt, principal amount (a) $ 49,187 $ 34,820 Net fair value adjustments related to hedging and purchase accounting 1,654 1,305 Net unamortized discounts, premiums and debt issuance costs (317 ) (176 ) Other long-term debt 5 5 Total long-term debt, carried at historical proceeds, as adjusted $ 50,529 $ 35,955 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 1,481 $ 1,462 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. Retirements In March 2020, we repurchased at par all $1.065 billion principal amount outstanding of our senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements. E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona and Chinese renminbi . As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) June 28, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,543 $ 551 $ 914 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 158 — 6,645 318 — 708 914 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,433 84 79 $ 19,623 82 55 Total $ 792 $ 993 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.2 billion as of June 28, 2020 and $5.9 billion as of December 31, 2019. The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 187 $ (204 ) $ 172 $ 48 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 13 28 14 32 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 6 483 — — — — Hedged item (6 ) (483 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — (144 ) (48 ) — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 29 52 42 31 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — — (16 ) — — Foreign currency long-term debt (e) — — (42 ) (27 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 8 (4 ) — — — — All other net (d) — — 12 — — — $ 8 $ (4 ) $ 56 $ (216 ) $ 228 $ 111 Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, Six Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ (341 ) $ 6 $ 126 $ 257 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 42 84 41 86 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 392 813 — — — — Hedged item (392 ) (813 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 240 (25 ) — — The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 176 93 84 55 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 8 19 — — Foreign currency long-term debt (e) — — 3 11 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (51 ) (124 ) — — — — All other net (d) — — 12 1 (1 ) — $ (51 ) $ (124 ) $ 139 $ 188 $ 251 $ 398 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive loss––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive loss––Foreign currency translation adjustments, net. (c) The amounts reclassified from OCI into COS were: • a net gain of $80 million in the second quarter of 2020 ; • a net gain of $150 million in the first six months of 2020 ; • a net gain of $59 million in the second quarter of 2019 ; and • a net gain of $103 million in the first six months of 2019 . The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $102 million within the next 12 months into income . The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) The amounts reclassified from OCI were reclassified into OID. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of June 28, 2020 , which are used as hedging instruments in net investment hedges. The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: June 28, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Short-term investments $ 45 $ — $ — $ — $ — $ — Long-term investments — — — 45 — — Long-term debt 2,023 140 1,181 7,092 266 690 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments. Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of June 28, 2020 , the aggregate fair value of these derivative financial instruments that are in a net liability position was $928 million , for which we have posted collateral of $922 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of June 28, 2020 , we received cash collateral of $858 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of certain credit risk related to certain significant customers, see Notes to Consolidated Financial Statements–– Note 17C. Segment, Geographic and Other Revenue Information: Other Revenue Information in Pfizer’s 2019 Financial Report. As of June 28, 2020 , we had amounts due from a well-diversified, high quality group of banks ( $1.9 billion ) from around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7E above.

Inventories

Inventories	6 Months Ended
	Jun. 28, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) June 28, December 31, Finished goods $ 3,002 $ 2,750 Work-in-process 4,810 4,743 Raw materials and supplies 752 790 Inventories (a) $ 8,564 $ 8,283 Noncurrent inventories not included above (b) $ 962 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	6 Months Ended
	Jun. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : June 28, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,927 $ (64,683 ) $ 25,244 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (757 ) 165 922 (741 ) 181 Licensing agreements and other (b) 2,327 (1,226 ) 1,101 1,772 (1,191 ) 582 93,176 (66,667 ) 26,509 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 4,518 4,518 5,919 5,919 Licensing agreements and other (b) 523 523 1,073 1,073 7,032 7,032 8,983 8,983 Identifiable intangible assets (c) $ 100,208 $ (66,667 ) $ 33,541 $ 100,408 $ (65,037 ) $ 35,370 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy. (b) The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array. (c) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: June 28, 2020 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 94 % — 6 % Licensing agreements and other, finite-lived 99 % 1 % 1 % Licensing agreements and other, indefinite-lived 100 % — — Amortization Total amortization expense for finite-lived intangible assets was $917 million for the second quarter of 2020 and $1.2 billion for the second quarter of 2019 , and $1.8 billion for the first six months of 2020 and $2.4 billion for the first six months of 2019 . B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2019 $ 48,202 $ 10,451 $ 58,653 Other (a) (155 ) (49 ) (204 ) Balance, June 28, 2020 $ 48,047 $ 10,401 $ 58,449 (a) Primarily represents the impact of foreign exchange.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	6 Months Ended
	Jun. 28, 2020
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, June 28, June 30, Service cost $ — $ — $ — $ — $ 36 $ 31 $ 10 $ 9 Interest cost 131 157 8 12 40 54 13 19 Expected return on plan assets (251 ) (223 ) — — (75 ) (80 ) (9 ) (8 ) Amortization of: Actuarial losses 32 37 4 2 30 20 — 1 Prior service credits (1 ) (1 ) — — (1 ) (1 ) (43 ) (45 ) Settlements 6 2 6 — 1 — — — Special termination benefits — 1 1 3 — — — 1 Net periodic benefit cost/(credit) reported in income $ (83 ) $ (27 ) $ 19 $ 17 $ 32 $ 25 $ (30 ) $ (23 ) Six Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, June 28, June 30, Service cost $ — $ — $ — $ — $ 72 $ 63 $ 19 $ 19 Interest cost 262 315 18 25 82 109 25 38 Expected return on plan assets (503 ) (445 ) — — (153 ) (160 ) (18 ) (16 ) Amortization of: Actuarial losses 64 74 7 5 62 41 — 2 Prior service credits (1 ) (2 ) — — (1 ) (2 ) (86 ) (89 ) Settlements 20 2 44 — 2 — — — Special termination benefits — 1 2 9 — — — 1 Net periodic benefit cost/(credit) reported in income $ (159 ) $ (55 ) $ 71 $ 37 $ 63 $ 51 $ (60 ) $ (46 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the six months ended June 28, 2020 $ 3 $ 150 $ 116 $ 64 Expected contributions from our general assets during 2020 (a) 1,253 183 185 137 (a) Contributions expected to be made for 2020 are inclusive of amounts contributed during the six months ended June 28, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Equity

Equity	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Equity	Equity A. Preferred Stock Prior to May 4, 2020, Pfizer’s Series A convertible perpetual preferred stock (the Series A Preferred Stock) was held by an employee stock ownership plan trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of Pfizer common stock on May 4, 2020. The Trust received an aggregate of 1,070,369 shares of Pfizer common stock upon conversion, with zero shares of Series A Preferred Stock remaining outstanding as a result of the conversion. B. Dividends The following table summarizes quarterly cash dividends: 2020 2019 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share December 13, 2019 March 6, 2020 0.38 December 14, 2018 March 1, 2019 0.36 April 23, 2020 June 5, 2020 0.38 April 25, 2019 June 7, 2019 0.36 June 25, 2020 September 1, 2020 0.38 June 27, 2019 September 3, 2019 0.36 September 24, 2019 December 2, 2019 0.36

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	6 Months Ended
	Jun. 28, 2020
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders The following table provides the detailed calculation of EPS : Three Months Ended Six Months Ended (IN MILLIONS) June 28, June 30, June 28, June 30, EPS Numerator––Basic Income from continuing operations $ 3,434 $ 5,056 $ 6,845 $ 8,945 Less: Net income attributable to noncontrolling interests 8 10 17 15 Income from continuing operations attributable to Pfizer Inc. 3,426 5,046 6,828 8,929 Less: Preferred stock dividends––net of tax — — — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,426 5,045 6,828 8,929 Discontinued operations––net of tax — — — — Net income attributable to Pfizer Inc. common shareholders $ 3,426 $ 5,045 $ 6,828 $ 8,929 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,426 $ 5,046 $ 6,828 $ 8,929 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — — — Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,426 $ 5,046 $ 6,828 $ 8,929 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,554 5,562 5,550 5,598 Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock 65 110 66 112 Weighted-average number of common shares outstanding––Diluted 5,619 5,672 5,616 5,711 Anti-dilutive common stock equivalents (a) 6 1 4 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Commi

Contingencies and Certain Commitments	6 Months Ended
	Jun. 28, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see Note 5B. For a discussion of our legal contingencies, see below. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to two patents. In June 2018, the PTAB ruled on another patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB’s ruling and requested that the PTAB redecide the challenge. In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We appealed. In January 2020, the U.S. Court of Appeals for the Federal Circuit vacated the original decision and requested that the PTAB redecide the case. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Xeljanz (tofacitinib) Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A.; and (v) Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. The remaining actions continue as described below. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. Inlyta (axitinib) In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Kerydin (tavaborole) In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary , filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia. Ibrance (palbociclib) In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of two composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Chantix (varenicline) In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware asserting the validity and infringement of three patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg and 1.0 mg tablets. Lyrica (pregabalin) In June 2014, Generics (U.K.) Ltd (trading as Mylan) filed an invalidity action against the Lyrica pain use patent in the High Court of Justice in London. Subsequently, Actavis Group PTC ehf filed an invalidity action in the same court, and Pfizer sued for infringement against Actavis Group PTC ehf, Actavis U.K. Ltd and Caduceus Pharma Ltd (together, Actavis), in addition to requesting preliminary relief. Our request for preliminary relief was denied in a January 2015 hearing, and the denial subsequently was confirmed on appeal. In February 2015, the National Health Service (NHS) England was ordered by the High Court, as an intermediary, to issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain. NHS Wales and NHS Northern Ireland also issued prescribing guidance. The guidance to prescribe and dispense Lyrica for neuropathic pain was withdrawn upon patent expiration in July 2017. We also filed infringement actions against (i) Teva UK Ltd, and (ii) Dr. Reddy’s Laboratories (UK) Ltd and Caduceus Pharma Ltd (together, Dr. Reddy’s) in February 2015, seeking the same relief as in the action against Actavis. Dr. Reddy’s filed an invalidity counterclaim. These actions were stayed pending the outcome of the Mylan and Actavis cases. The Mylan and Actavis invalidity actions were heard in the High Court at the same time as the Actavis infringement action. The High Court ruled against us, holding that the asserted claims were either not infringed or invalid, and appeals followed. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid. In October 2015, after Sandoz GmbH and Sandoz Ltd (together, Sandoz) launched a full label generic pregabalin product, we obtained from the High Court a preliminary injunction enjoining Sandoz from further sales of the product and ordering Sandoz to identify the parties holding its product. Sandoz identified wholesaler AAH Pharmaceuticals Ltd and pharmacy chain Lloyds Pharmacy Ltd (supplied by AAH), and we requested that these parties cease further sales and withdraw the Sandoz full label product. In October 2015, Lloyds was added to the Sandoz action, and we obtained a preliminary order from the High Court requiring Lloyds to advise its pharmacists that the Sandoz full label product should not be dispensed. In November 2015, the High Court confirmed the preliminary injunction against Sandoz and Lloyds. Sandoz filed an invalidity counterclaim. Upon agreement of the parties, in December 2015, the proceedings against Lloyds were discontinued, and the proceedings against Sandoz were stayed pending outcome of the Mylan and Actavis cases. The preliminary injunction against Sandoz remained in place until patent expiration in July 2017. In May 2020, Dr. Reddy’s filed a claim for damages in connection with the above-referenced legal actions. In July 2020, the Scottish Ministers and fourteen Scottish Health Boards (together, NHS Scotland) filed a claim for damages in connection with the above-referenced legal action concerning Sandoz. Matter Involving Our Collaboration/Licensing Partners Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. The decision is subject to appeal. Prior to the August 2020 ruling, we and BMS settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision. Viagra Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California ( In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 ), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation (In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691 ). In January 2020, the District Court granted our and Lilly’s motion to exclude all of plaintiffs’ general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs’ claims. In April 2020, plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. EpiPen Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants’ allegedly unlawful conduct. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer’s and/or its affiliates’ settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In August 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation ( In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785 ) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties. In July 2020, a new lawsuit was filed in the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class. Nexium 24HR and Protonix A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In re: Proton-Pump Inhibitor Products Liability Litigation (No. II)) in the U.S. District Court for the District of New Jersey. On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR. Docetaxel • Personal Injury Actions A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740 ) in the U.S. District Court for the Eastern District of Louisiana. • Mississippi Attorney General Government Action In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief. Array Securities Litigation In November 2017, two purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. Zantac A number of lawsuits have been filed a

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	6 Months Ended
	Jun. 28, 2020
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of three distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Pfizer’s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through July 31, 2019 Consumer Healthcare was, responsible for its own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. For additional information, see Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, and Note 2 . Operating Segments Some additional information about our Biopharma and Upjohn business segments follows: Pfizer Biopharmaceuticals Group Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients’ lives. Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone. Select products include: - Ibrance - Eliquis - Prevnar 13/Prevenar 13 - Xeljanz - Enbrel (outside the U.S. and Canada) - Vyndaqel/Vyndamax - Chantix/Champix - Xtandi - Sutent Select products include: - Lipitor - Lyrica - Celebrex - Viagra - Certain generic medicines Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines. • GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies. • Other––the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. • Corporate and Other Unallocated––the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $178 billion as of June 28, 2020 and $167 billion as of December 31, 2019 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 9,795 $ 9,432 $ 6,650 $ 6,071 Upjohn 2,006 2,970 1,168 1,973 Total reportable segments 11,801 12,402 7,818 8,044 Other business activities — 862 (1,530 ) (1,193 ) Reconciling Items: Corporate and other unallocated — — (1,136 ) (1,399 ) Purchase accounting adjustments — — (910 ) (1,178 ) Acquisition-related costs — — (21 ) 176 Certain significant items (b) — — (268 ) (309 ) $ 11,801 $ 13,264 $ 3,953 $ 4,141 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 19,802 $ 18,477 $ 13,379 $ 11,954 Upjohn 4,027 6,184 2,359 4,251 Total reportable segments 23,829 24,661 15,738 16,206 Other business activities — 1,721 (3,019 ) (2,306 ) Reconciling Items: Corporate and other unallocated — — (2,245 ) (2,676 ) Purchase accounting adjustments — — (1,722 ) (2,217 ) Acquisition-related costs — — (34 ) 148 Certain significant items (b) — — (879 ) (691 ) $ 23,829 $ 26,382 $ 7,838 $ 8,463 (a) Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019 , and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information The following table provides revenues by geographic area: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, % Change June 28, June 30, % Change United States $ 5,402 $ 6,335 (15 ) $ 11,053 $ 12,510 (12 ) Developed Europe (a) 2,088 2,228 (6 ) 4,009 4,315 (7 ) Developed Rest of World (b) 1,552 1,639 (5 ) 3,008 3,174 (5 ) Emerging Markets (c) 2,759 3,062 (10 ) 5,759 6,383 (10 ) Revenues $ 11,801 $ 13,264 (11 ) $ 23,829 $ 26,382 (10 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019 , and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey. C. Other Revenue Information Significant Product Revenues The following table provides detailed revenue information for several of our major products: (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATION OR CLASS June 28, June 30, June 28, June 30, TOTAL REVENUES $ 11,801 $ 13,264 $ 23,829 $ 26,382 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) $ 9,795 $ 9,432 $ 19,802 $ 18,477 Internal Medicine (a) $ 2,279 $ 2,243 $ 4,610 $ 4,380 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,272 1,085 2,572 2,096 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 235 276 505 549 Premarin family Symptoms of menopause 152 193 304 361 BMP2 Development of bone and cartilage 57 79 127 145 Toviaz Overactive bladder 64 65 124 125 All other Internal Medicine Various 498 544 978 1,103 Oncology $ 2,647 $ 2,236 $ 5,082 $ 4,198 Ibrance Metastatic breast cancer 1,349 1,261 2,598 2,394 Xtandi alliance revenues Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer 266 201 475 369 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 209 248 414 480 Inlyta Advanced RCC 195 104 364 177 Xalkori ALK-positive and ROS1-positive advanced NSCLC 138 133 287 255 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 113 97 213 177 Retacrit (b) Anemia 87 51 176 82 Braftovi In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy 36 — 74 — Mektovi In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation 32 — 69 — All other Oncology Various 221 140 412 262 Hospital (a), (c) $ 1,794 $ 1,838 $ 3,807 $ 3,665 Sulperazon Bacterial infections 102 165 289 342 Medrol Anti-inflammatory glucocorticoid 78 120 207 240 Zithromax Bacterial infections 55 73 193 177 Precedex Sedation agent in surgery or intensive care 114 40 156 80 Vfend Fungal infections 75 94 149 178 Panzyga Primary humoral immunodeficiency 63 44 136 61 (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATION OR CLASS June 28, June 30, June 28, June 30, Zyvox Bacterial infections 55 71 125 134 Fragmin Treatment/prevention of venous thromboembolism 58 63 118 123 Pfizer CentreOne (d) Various 224 204 376 380 All other Anti-infectives Various 367 420 811 825 All other Hospital (c) Various 603 544 1,245 1,124 Vaccines $ 1,247 $ 1,375 $ 2,857 $ 2,988 Prevnar 13/Prevenar 13 Pneumococcal disease 1,116 1,179 2,566 2,665 Nimenrix Meningococcal disease 56 58 130 107 All other Vaccines Various 75 138 161 215 Inflammation & Immunology (I&I) $ 1,149 $ 1,219 $ 2,127 $ 2,256 Xeljanz RA, PsA, UC 635 613 1,086 1,036 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 337 420 684 871 Inflectra/Remsima (b) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 150 153 308 291 All other I&I Various 26 34 48 59 Rare Disease $ 681 $ 521 $ 1,319 $ 991 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 277 63 508 104 BeneFIX Hemophilia B 109 121 230 247 Genotropin Replacement of human growth hormone 106 125 209 232 Refacto AF/Xyntha Hemophilia A 91 108 181 214 Somavert Acromegaly 67 68 131 128 All other Rare Disease Various 31 35 61 66 UPJOHN (a) $ 2,006 $ 2,970 $ 4,027 $ 6,184 Lipitor Reduction of LDL cholesterol 431 407 836 1,029 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 349 1,175 706 2,362 Norvasc Hypertension 222 216 419 516 Celebrex Arthritis pain and inflammation, acute pain 139 174 295 347 Viagra Erectile dysfunction 94 114 222 259 Effexor Depression and certain anxiety disorders 86 86 163 163 Zoloft Depression and certain anxiety disorders 79 73 157 143 EpiPen (a) Epinephrine injection used in treatment of life-threatening allergic reactions 64 67 136 123 Xalatan/Xalacom Glaucoma and ocular hypertension 65 72 126 133 All other Upjohn Various 476 587 968 1,109 CONSUMER HEALTHCARE BUSINESS (e) $ — $ 862 $ — $ 1,721 Total Alliance revenues $ 1,404 $ 1,187 $ 2,786 $ 2,277 Total Biosimilars (b) $ 289 $ 217 $ 578 $ 396 Total Sterile Injectable Pharmaceuticals (f) $ 1,237 $ 1,218 $ 2,644 $ 2,455 (a) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation. (b) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (c) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (d) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements. (e) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B . (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 24, 2020 and May 26, 2019 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended June 28, 2020 and June 30, 2019 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2019 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see Note 14 . Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements. For additional information, see Note 14. Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. For additional information, see Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, and Note 2 . Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Adoption of New Accounting Standards	Adoption of New Accounting Standards in 2020 On January 1, 2020 , we adopted four new accounting standards. Credit Losses on Financial Instruments ––We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer’s credit improves. We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of Retained earnings was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income for the three and six months ended June 28, 2020 or condensed consolidated statement of cash flows for the six months ended June 28, 2020 , nor on our condensed consolidated balance sheet as of June 28, 2020 . For additional information, see Note 1C . Goodwill Impairment Testing ––We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Implementation Costs in a Cloud Computing Arrangement ––We prospectively adopted the new standard related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements. Collaboration Agreements ––We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2019, we adopted four new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 included in our 2019 Financial Report. C. Revenues and Trade Accounts Receivable Deductions from Revenues–– Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.5 billion as of June 28, 2020 and $5.7 billion as of December 31, 2019 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) June 28, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,129 $ 1,257 Other current liabilities : Accrued rebates 3,210 3,285 Other accruals 576 581 Other noncurrent liabilities 598 565 Total accrued rebates and other accruals $ 5,512 $ 5,689 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. During the three and six months ended June 28, 2020 , additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) June 28, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,129 $ 1,257 Other current liabilities : Accrued rebates 3,210 3,285 Other accruals 576 581 Other noncurrent liabilities 598 565 Total accrued rebates and other accruals $ 5,512 $ 5,689

Acquisition, Equity-Method In_2

Acquisition, Equity-Method Investment and Licensing Arrangements - (Tables)	6 Months Ended
	Jun. 28, 2020
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Equity Method Investment	Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows: (MILLIONS OF DOLLARS) March 31, Current assets $ 8,213 Noncurrent assets 37,627 Total assets $ 45,840 Current liabilities $ 5,524 Noncurrent liabilities 5,152 Total liabilities $ 10,677 Equity attributable to shareholders $ 35,031 Equity attributable to noncontrolling interests 133 Total net equity $ 35,163 (MILLIONS OF DOLLARS) Three Months Ended March 31, 2020 Six Months Ended March 31, 2020 Net sales $ 3,503 $ 6,691 Cost of sales (1,394 ) (3,205 ) Gross profit $ 2,109 $ 3,486 Income from continuing operations 425 471 Net income 425 471 Income attributable to shareholders 405 441

Restructuring Charges and Oth_2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	6 Months Ended
	Jun. 28, 2020
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Restructuring charges/(credits): Employee terminations $ 346 $ (166 ) $ 371 $ (167 ) Asset impairments (8 ) (9 ) 23 — Exit costs 1 31 1 34 Restructuring charges (a) 340 (144 ) 396 (134 ) Transaction costs (b) 11 — 14 — Integration costs and other (c) 11 29 21 64 Restructuring charges and certain acquisition-related costs 362 (115 ) 431 (69 ) Net periodic benefit costs recorded in Other (income)/deductions––net 5 4 29 10 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 4 7 10 15 Selling, informational and administrative expenses — 1 — 2 Research and development expenses 2 2 (3 ) 5 Total additional depreciation––asset restructuring 6 10 6 23 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 11 17 21 31 Selling, informational and administrative expenses 63 16 78 25 Research and development expenses 1 9 1 13 Total implementation costs 75 42 99 69 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 449 $ (59 ) $ 566 $ 32 (a) In the second quarter and first six months of 2020 , restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the second quarter and first six months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report. The restructuring activities for 2020 are associated with the following: • For the second quarter of 2020 , Biopharma ( $12 million credit); Upjohn ( $1 million credit); and Other ( $352 million charge). • For the first six months of 2020 , Biopharma ( $9 million credit); Upjohn ( $12 million charge); and Other ( $393 million charge). The restructuring activities for 2019 are associated with the following: • For the second quarter of 2019 , Biopharma ( $62 million credit); Upjohn ( $9 million credit); and Other ( $74 million credit). • For the first six months of 2019 , Biopharma ( $48 million credit); Upjohn ( $22 million credit); and Other ( $63 million credit). Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the second quarter and first six months of 2020 , restructuring costs identified as Other primarily relate to corporate enabling functions. (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the second quarter and first six months of 2020 , integration costs and other were mostly related to our acquisition of Array. In the second quarter and first six months of 2019 , integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2019 (a) $ 887 $ — $ 46 $ 933 Provision 371 23 1 396 Utilization and other (b) (341 ) (23 ) (14 ) (378 ) Balance, June 28, 2020 (c) $ 918 $ — $ 34 $ 951 (a) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $625 million ) and Other noncurrent liabilities ( $326 million ).

Other (Income)_Deductions - N_2

Other (Income)/Deductions - Net (Tables)	6 Months Ended
	Jun. 28, 2020
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Interest income (a) $ (19 ) $ (59 ) $ (53 ) $ (125 ) Interest expense (a) 372 389 762 750 Net interest expense 353 330 709 625 Royalty-related income (b) (191 ) (231 ) (311 ) (320 ) Net (gains)/losses on asset disposals 1 — 2 (1 ) Net gains recognized during the period on equity securities (c) (732 ) (36 ) (478 ) (147 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (d) (100 ) (22 ) (215 ) (104 ) Net periodic benefit credits other than service costs (e) (108 ) (51 ) (175 ) (91 ) Certain legal matters, net 17 15 26 19 Certain asset impairments (f) — 10 — 160 Business and legal entity alignment costs (g) — 137 — 256 Net losses on early retirement of debt — — — 138 GSK Consumer Healthcare JV equity method (income)/loss (h) (126 ) — (92 ) — Other, net (i) 25 (27 ) (107 ) (318 ) Other (income)/deductions––net $ (862 ) $ 126 $ (641 ) $ 218 (a) Interest income decreased in the second quarter and first six months of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the second quarter of 2020 mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of 2020 , mainly as a result of an increased commercial paper balance due to the acquisition of Array. (b) Royalty-related income for the second quarter and first six months of 2019 included a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million . (c) The gains in the second quarter of 2020 include, among other things, unrealized gains of $508 million related to our investment in Allogene and unrealized gains of $61 million related to our investment in BioNTech. The gains in the first six months of 2020 include, among other things, unrealized gains of $374 million related to our investment in Allogene and unrealized gains of $127 million related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of $104 million related to our investment in Cortexyme, Inc. For additional information on investments, see Note 7B . (d) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter and first six months of 2020 , mainly includes, among other things, $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first six months of 2020 also includes an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first six months of 2019 , primarily included $68 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® . (e) For additional information, see Note 10 . (f) The first six months of 2019 included intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development, (ii) $40 million related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) $10 million related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflected , among other things, updated commercial forecasts. In addition, the first six months of 2019 included other asset impairments of $20 million . (g) In the second quarter and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. (h) Includes our share of the GSK Consumer Healthcare joint venture’s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See Note 2B for additional information. (i) The second quarter of 2020 includes, among other things, dividend income of $76 million from our investment in ViiV, and charges of $86 million , reflecting the change in the fair value of contingent consideration. The first six months of 2020 includes, among other things, dividend income of $153 million from our investment in ViiV and charges of $99 million , reflecting the change in the fair value of contingent consideration. The second quarter of 2019 included, among other things, charges of $81 million , reflecting the change in the fair value of contingent consideration, dividend income of $76 million from our investment in ViiV, and $25 million of income from insurance recoveries related to Hurricane Maria. The first six months of 2019 included, among other things, dividend income of $140 million from our investment in ViiV and $50 million of income from insurance recoveries related to Hurricane Maria.

Tax Matters (Tables)

Tax Matters (Tables)	6 Months Ended
	Jun. 28, 2020
Income Tax Disclosure [Abstract]
Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision/(benefit) on other comprehensive loss : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Foreign currency translation adjustments, net (a) $ 60 $ (17 ) $ (192 ) $ 10 Unrealized holding gains/(losses) on derivative financial instruments, net 51 (53 ) (82 ) 6 Reclassification adjustments for gains included in net income (35 ) (4 ) (20 ) (59 ) 16 (57 ) (102 ) (53 ) Unrealized holding gains/(losses) on available-for-sale securities, net 5 (1 ) (1 ) 4 Reclassification adjustments for losses included in net income 6 3 7 5 11 2 6 9 Benefit plans: actuarial gains/(losses), net 2 (1 ) (19 ) (1 ) Reclassification adjustments related to amortization 16 15 31 18 Reclassification adjustments related to settlements, net 2 — 12 1 Other 16 8 20 3 35 23 43 21 Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) (21 ) (22 ) Other 1 — 1 — (9 ) (11 ) (20 ) (22 ) Tax provision/(benefit) on other comprehensive loss $ 113 $ (59 ) $ (265 ) $ (34 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2019 $ (5,952 ) $ 20 $ (35 ) $ (6,257 ) $ 584 $ (11,640 ) Other comprehensive income/(loss) (a) (1,310 ) (353 ) 44 79 (65 ) (1,605 ) Balance, June 28, 2020 $ (7,262 ) $ (333 ) $ 9 $ (6,178 ) $ 518 $ (13,246 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $12 million loss for the first six months of 2020. Includes after-tax losses of approximately $902 million related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), and losses from the weakening of certain major currencies against the U.S. dollar. These losses were partially offset by the results of our net investment hedging program.

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 28, 2020
Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in our 2019 Financial Report: June 28, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds (a) $ 13,033 $ — $ 13,033 $ 705 $ — $ 705 Classified as available-for-sale debt securities: Government and agency—non-U.S. 6,218 — 6,218 4,863 — 4,863 Government and agency—U.S. 14 — 14 811 — 811 Corporate and other 1,440 — 1,440 1,013 — 1,013 7,672 — 7,672 6,687 — 6,687 Total short-term investments 20,705 — 20,705 7,392 — 7,392 Other current assets Derivative assets: Interest rate contracts 17 — 17 53 — 53 Foreign exchange contracts 413 — 413 413 — 413 Total other current assets 431 — 431 465 — 465 Long-term investments Classified as equity securities with readily determinable fair values (b) 2,072 2,046 26 1,902 1,863 39 Classified as available-for-sale debt securities: Government and agency—U.S. 243 — 243 303 — 303 Corporate and other 11 — 11 11 — 11 254 — 254 315 — 315 Total long-term investments 2,326 2,046 280 2,216 1,863 354 Other noncurrent assets Derivative assets: Interest rate contracts 140 — 140 266 — 266 Foreign exchange contracts 221 — 221 261 — 261 Total derivative assets 362 — 362 526 — 526 Insurance contracts (c) 578 — 578 575 — 575 Total other noncurrent assets 940 — 940 1,102 — 1,102 Total assets $ 24,402 $ 2,046 $ 22,355 $ 11,176 $ 1,863 $ 9,313 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 127 $ — $ 127 $ 114 $ — $ 114 Total other current liabilities 127 — 127 114 — 114 Other noncurrent liabilities Derivative liabilities: Foreign exchange contracts 866 — 866 604 — 604 Total other noncurrent liabilities 866 — 866 604 — 604 Total liabilities $ 993 $ — $ 993 $ 718 $ — $ 718 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. (b) As of June 28, 2020 , long-term equity securities of $163 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. (c) Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the condensed consolidated statements of income (see Note 4 ).
Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: June 28, 2020 December 31, 2019 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion (a) $ 50,529 $ 59,121 $ 59,121 $ 35,955 $ 40,842 $ 40,842 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.
Investments by Classification Type	The following table represents our investments by classification type: (MILLIONS OF DOLLARS) June 28, December 31, Short-term investments Equity securities with readily determinable fair values (a) $ 13,033 $ 705 Available-for-sale debt securities 7,672 6,687 Held-to-maturity debt securities 288 1,133 Total Short-term investments $ 20,993 $ 8,525 Long-term investments Equity securities with readily determinable fair values $ 2,072 $ 1,902 Available-for-sale debt securities 254 315 Held-to-maturity debt securities 43 42 Private equity securities at cost 772 756 Total Long-term investments $ 3,142 $ 3,014 Equity-method investments 15,578 17,133 Total long-term investments and equity-method investments $ 18,720 $ 20,147 Held-to-maturity cash equivalents $ 119 $ 163 (a) As of June 28, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet. .
Schedule of Held-to-maturity Securities	At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: June 28, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 6,209 $ 12 $ (3 ) $ 6,218 $ 6,218 $ — $ — $ 6,218 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 257 1 (1 ) 257 14 243 — 257 1,120 — (6 ) 1,114 Corporate and other (a) 1,450 2 (1 ) 1,451 1,440 11 — 1,451 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 228 — — 228 189 9 30 228 535 — — 535 Government and agency –– non-U.S. 222 — — 222 218 — 4 222 803 — — 803 Total debt securities $ 8,366 $ 16 $ (5 ) $ 8,376 $ 8,079 $ 263 $ 35 $ 8,376 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Schedule of Available-for-sale Securities	At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: June 28, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 6,209 $ 12 $ (3 ) $ 6,218 $ 6,218 $ — $ — $ 6,218 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 257 1 (1 ) 257 14 243 — 257 1,120 — (6 ) 1,114 Corporate and other (a) 1,450 2 (1 ) 1,451 1,440 11 — 1,451 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 228 — — 228 189 9 30 228 535 — — 535 Government and agency –– non-U.S. 222 — — 222 218 — 4 222 803 — — 803 Total debt securities $ 8,366 $ 16 $ (5 ) $ 8,376 $ 8,079 $ 263 $ 35 $ 8,376 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At June 28, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at June 28, 2020 and December 31, 2019 is as follows, including, as of June 28, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: June 28, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 6,209 $ 12 $ (3 ) $ 6,218 $ 6,218 $ — $ — $ 6,218 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 257 1 (1 ) 257 14 243 — 257 1,120 — (6 ) 1,114 Corporate and other (a) 1,450 2 (1 ) 1,451 1,440 11 — 1,451 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 228 — — 228 189 9 30 228 535 — — 535 Government and agency –– non-U.S. 222 — — 222 218 — 4 222 803 — — 803 Total debt securities $ 8,366 $ 16 $ (5 ) $ 8,376 $ 8,079 $ 263 $ 35 $ 8,376 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Schedule of Gains and Losses on Investment Securities	The following table presents the calculation of the portion of unrealized gains for the period that relates to equity securities, excluding equity method investments, still held at the reporting date: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Net gains recognized during the period on equity securities (a ) $ (732 ) $ (36 ) $ (478 ) $ (147 ) Less: Net (gains)/losses recognized during the period on equity securities sold during the period 1 (6 ) (18 ) (10 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date (b) $ (733 ) $ (31 ) $ (459 ) $ (137 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . (b) Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $67 million and upward adjustments of $66 million . Impairments, downward and upward adjustments were not significant in the second quarter and the first six months of 2020 and 2019 .
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS OF DOLLARS) June 28, December 31, Commercial paper $ 10,660 $ 13,915 Current portion of long-term debt, principal amount 1,481 1,458 Other short-term borrowings, principal amount (a) 956 860 Total short-term borrowings, principal amount 13,097 16,233 Net fair value adjustments related to hedging and purchase accounting 1 5 Net unamortized discounts, premiums and debt issuance costs (14 ) (43 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 13,084 $ 16,195 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	In the second quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of June 28, 2020 Pfizer Inc. (a) 0.800% May 28, 2025 $ 750 1.700% May 28, 2030 1,000 2.550% May 28, 2040 1,000 2.700% May 28, 2050 1,250 $ 4,000 Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc. (b) 1.125% June 22, 2022 $ 1,000 1.650% June 22, 2025 750 2.300% June 22, 2027 750 2.700% June 22, 2030 1,450 3.850% June 22, 2040 1,500 4.000% June 22, 2050 2,000 $ 7,450 Upjohn Finance B.V., a wholly-owned subsidiary of Upjohn Inc. (b) 0.816% June 23, 2022 € 750 1.023% June 23, 2024 750 1.362% June 23, 2027 850 1.908% June 23, 2032 1,250 € 3,600 (a) The notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rate for the notes at issuance was 2.11% . (b) In June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings in connection with the previously announced proposed Reverse Morris Trust transaction that will ultimately combine Upjohn and Mylan to form a new company, Viatris. The notes may be redeemed by Upjohn Inc. and Upjohn Finance B.V., as applicable, at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. The weighted-average effective interest rates at issuance were 2.95% for the $7.45 billion notes and 1.37% for the €3.60 billion notes. If the proposed transaction with Mylan does not close on or prior to February 1, 2021, or if, prior to such date, Upjohn Inc. and Mylan notify the trustee that the business combination agreement for the proposed transaction with Mylan is terminated, or the transaction will not otherwise be pursued, the notes must be redeemed at redemption prices equal to 101% of their respective principal amounts, plus accrued and unpaid interest. Pfizer has guaranteed these notes, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the proposed distribution to Pfizer’s stockholders of all of the issued and outstanding shares of Upjohn Inc.’s common stock held by Pfizer (the Distribution). Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor. The proceeds from the financings will be used in part to fund a cash distribution from Upjohn Inc. to Pfizer immediately prior to the Distribution. In the interim, the $11.4 billion of proceeds are classified as Restricted short-term investments in the condensed consolidated balance sheet as of June 28, 2020 pursuant to the terms of the transaction agreements. In the first quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of June 28, 2020 2.625% (a) April 1, 2030 $ 1,250 Total long-term debt issued in the first quarter of 2020 (b) $ 1,250 (a) The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest. (b) The effective interest rate for the notes at issuance was 2.67% . The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) June 28, December 31, Total long-term debt, principal amount (a) $ 49,187 $ 34,820 Net fair value adjustments related to hedging and purchase accounting 1,654 1,305 Net unamortized discounts, premiums and debt issuance costs (317 ) (176 ) Other long-term debt 5 5 Total long-term debt, carried at historical proceeds, as adjusted $ 50,529 $ 35,955 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 1,481 $ 1,462 (a) As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.
Schedule of Derivative Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) June 28, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,543 $ 551 $ 914 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 158 — 6,645 318 — 708 914 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,433 84 79 $ 19,623 82 55 Total $ 792 $ 993 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.2 billion as of June 28, 2020 and $5.9 billion as of December 31, 2019.
Schedule of Derivative Assets	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) June 28, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,543 $ 551 $ 914 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 158 — 6,645 318 — 708 914 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,433 84 79 $ 19,623 82 55 Total $ 792 $ 993 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.2 billion as of June 28, 2020 and $5.9 billion as of December 31, 2019.
Schedule of Derivative Liabilities	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) June 28, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 22,543 $ 551 $ 914 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 158 — 6,645 318 — 708 914 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,433 84 79 $ 19,623 82 55 Total $ 792 $ 993 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.2 billion as of June 28, 2020 and $5.9 billion as of December 31, 2019.
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 187 $ (204 ) $ 172 $ 48 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 13 28 14 32 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 6 483 — — — — Hedged item (6 ) (483 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — (144 ) (48 ) — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 29 52 42 31 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — — (16 ) — — Foreign currency long-term debt (e) — — (42 ) (27 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 8 (4 ) — — — — All other net (d) — — 12 — — — $ 8 $ (4 ) $ 56 $ (216 ) $ 228 $ 111 Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, Six Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ (341 ) $ 6 $ 126 $ 257 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 42 84 41 86 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 392 813 — — — — Hedged item (392 ) (813 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 240 (25 ) — — The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 176 93 84 55 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 8 19 — — Foreign currency long-term debt (e) — — 3 11 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (51 ) (124 ) — — — — All other net (d) — — 12 1 (1 ) — $ (51 ) $ (124 ) $ 139 $ 188 $ 251 $ 398 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive loss––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive loss––Foreign currency translation adjustments, net. (c) The amounts reclassified from OCI into COS were: • a net gain of $80 million in the second quarter of 2020 ; • a net gain of $150 million in the first six months of 2020 ; • a net gain of $59 million in the second quarter of 2019 ; and • a net gain of $103 million in the first six months of 2019 . The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $102 million within the next 12 months into income . The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) The amounts reclassified from OCI were reclassified into OID. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of June 28, 2020 , which are used as hedging instruments in net investment hedges.
Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded	The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: June 28, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Short-term investments $ 45 $ — $ — $ — $ — $ — Long-term investments — — — 45 — — Long-term debt 2,023 140 1,181 7,092 266 690 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 28, 2020
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) June 28, December 31, Finished goods $ 3,002 $ 2,750 Work-in-process 4,810 4,743 Raw materials and supplies 752 790 Inventories (a) $ 8,564 $ 8,283 Noncurrent inventories not included above (b) $ 962 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) June 28, December 31, Finished goods $ 3,002 $ 2,750 Work-in-process 4,810 4,743 Raw materials and supplies 752 790 Inventories (a) $ 8,564 $ 8,283 Noncurrent inventories not included above (b) $ 962 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_2

Identifiable Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : June 28, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,927 $ (64,683 ) $ 25,244 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (757 ) 165 922 (741 ) 181 Licensing agreements and other (b) 2,327 (1,226 ) 1,101 1,772 (1,191 ) 582 93,176 (66,667 ) 26,509 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 4,518 4,518 5,919 5,919 Licensing agreements and other (b) 523 523 1,073 1,073 7,032 7,032 8,983 8,983 Identifiable intangible assets (c) $ 100,208 $ (66,667 ) $ 33,541 $ 100,408 $ (65,037 ) $ 35,370 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy. (b) The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array. (c) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : June 28, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,927 $ (64,683 ) $ 25,244 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (757 ) 165 922 (741 ) 181 Licensing agreements and other (b) 2,327 (1,226 ) 1,101 1,772 (1,191 ) 582 93,176 (66,667 ) 26,509 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 4,518 4,518 5,919 5,919 Licensing agreements and other (b) 523 523 1,073 1,073 7,032 7,032 8,983 8,983 Identifiable intangible assets (c) $ 100,208 $ (66,667 ) $ 33,541 $ 100,408 $ (65,037 ) $ 35,370 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy. (b) The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array. (c) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: June 28, 2020 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 94 % — 6 % Licensing agreements and other, finite-lived 99 % 1 % 1 % Licensing agreements and other, indefinite-lived 100 % — —
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2019 $ 48,202 $ 10,451 $ 58,653 Other (a) (155 ) (49 ) (204 ) Balance, June 28, 2020 $ 48,047 $ 10,401 $ 58,449 (a) Primarily represents the impact of foreign exchange.

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	6 Months Ended
	Jun. 28, 2020
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, June 28, June 30, Service cost $ — $ — $ — $ — $ 36 $ 31 $ 10 $ 9 Interest cost 131 157 8 12 40 54 13 19 Expected return on plan assets (251 ) (223 ) — — (75 ) (80 ) (9 ) (8 ) Amortization of: Actuarial losses 32 37 4 2 30 20 — 1 Prior service credits (1 ) (1 ) — — (1 ) (1 ) (43 ) (45 ) Settlements 6 2 6 — 1 — — — Special termination benefits — 1 1 3 — — — 1 Net periodic benefit cost/(credit) reported in income $ (83 ) $ (27 ) $ 19 $ 17 $ 32 $ 25 $ (30 ) $ (23 ) Six Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, June 28, June 30, June 28, June 30, Service cost $ — $ — $ — $ — $ 72 $ 63 $ 19 $ 19 Interest cost 262 315 18 25 82 109 25 38 Expected return on plan assets (503 ) (445 ) — — (153 ) (160 ) (18 ) (16 ) Amortization of: Actuarial losses 64 74 7 5 62 41 — 2 Prior service credits (1 ) (2 ) — — (1 ) (2 ) (86 ) (89 ) Settlements 20 2 44 — 2 — — — Special termination benefits — 1 2 9 — — — 1 Net periodic benefit cost/(credit) reported in income $ (159 ) $ (55 ) $ 71 $ 37 $ 63 $ 51 $ (60 ) $ (46 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the six months ended June 28, 2020 $ 3 $ 150 $ 116 $ 64 Expected contributions from our general assets during 2020 (a) 1,253 183 185 137
Schedule of Employer Contributions to Pension and Postretirement Plans	The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the six months ended June 28, 2020 $ 3 $ 150 $ 116 $ 64 Expected contributions from our general assets during 2020 (a) 1,253 183 185 137 (a) Contributions expected to be made for 2020 are inclusive of amounts contributed during the six months ended June 28, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Equity - (Tables)

Equity - (Tables)	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Schedule of Dividends	The following table summarizes quarterly cash dividends: 2020 2019 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share December 13, 2019 March 6, 2020 0.38 December 14, 2018 March 1, 2019 0.36 April 23, 2020 June 5, 2020 0.38 April 25, 2019 June 7, 2019 0.36 June 25, 2020 September 1, 2020 0.38 June 27, 2019 September 3, 2019 0.36 September 24, 2019 December 2, 2019 0.36

Earnings Per Common Share Att_2

Earnings Per Common Share Attributable to Common Shareholders (Tables)	6 Months Ended
	Jun. 28, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of EPS : Three Months Ended Six Months Ended (IN MILLIONS) June 28, June 30, June 28, June 30, EPS Numerator––Basic Income from continuing operations $ 3,434 $ 5,056 $ 6,845 $ 8,945 Less: Net income attributable to noncontrolling interests 8 10 17 15 Income from continuing operations attributable to Pfizer Inc. 3,426 5,046 6,828 8,929 Less: Preferred stock dividends––net of tax — — — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,426 5,045 6,828 8,929 Discontinued operations––net of tax — — — — Net income attributable to Pfizer Inc. common shareholders $ 3,426 $ 5,045 $ 6,828 $ 8,929 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,426 $ 5,046 $ 6,828 $ 8,929 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — — — Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,426 $ 5,046 $ 6,828 $ 8,929 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,554 5,562 5,550 5,598 Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock 65 110 66 112 Weighted-average number of common shares outstanding––Diluted 5,619 5,672 5,616 5,711 Anti-dilutive common stock equivalents (a) 6 1 4 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other_2

Segment, Geographic and Other Revenue Information (Tables)	6 Months Ended
	Jun. 28, 2020
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 9,795 $ 9,432 $ 6,650 $ 6,071 Upjohn 2,006 2,970 1,168 1,973 Total reportable segments 11,801 12,402 7,818 8,044 Other business activities — 862 (1,530 ) (1,193 ) Reconciling Items: Corporate and other unallocated — — (1,136 ) (1,399 ) Purchase accounting adjustments — — (910 ) (1,178 ) Acquisition-related costs — — (21 ) 176 Certain significant items (b) — — (268 ) (309 ) $ 11,801 $ 13,264 $ 3,953 $ 4,141 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 19,802 $ 18,477 $ 13,379 $ 11,954 Upjohn 4,027 6,184 2,359 4,251 Total reportable segments 23,829 24,661 15,738 16,206 Other business activities — 1,721 (3,019 ) (2,306 ) Reconciling Items: Corporate and other unallocated — — (2,245 ) (2,676 ) Purchase accounting adjustments — — (1,722 ) (2,217 ) Acquisition-related costs — — (34 ) 148 Certain significant items (b) — — (879 ) (691 ) $ 23,829 $ 26,382 $ 7,838 $ 8,463 (a) Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019 , and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 9,795 $ 9,432 $ 6,650 $ 6,071 Upjohn 2,006 2,970 1,168 1,973 Total reportable segments 11,801 12,402 7,818 8,044 Other business activities — 862 (1,530 ) (1,193 ) Reconciling Items: Corporate and other unallocated — — (1,136 ) (1,399 ) Purchase accounting adjustments — — (910 ) (1,178 ) Acquisition-related costs — — (21 ) 176 Certain significant items (b) — — (268 ) (309 ) $ 11,801 $ 13,264 $ 3,953 $ 4,141 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) June 28, June 30, June 28, June 30, Reportable Segments: Biopharma $ 19,802 $ 18,477 $ 13,379 $ 11,954 Upjohn 4,027 6,184 2,359 4,251 Total reportable segments 23,829 24,661 15,738 16,206 Other business activities — 1,721 (3,019 ) (2,306 ) Reconciling Items: Corporate and other unallocated — — (2,245 ) (2,676 ) Purchase accounting adjustments — — (1,722 ) (2,217 ) Acquisition-related costs — — (34 ) 148 Certain significant items (b) — — (879 ) (691 ) $ 23,829 $ 26,382 $ 7,838 $ 8,463 (a) Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019 , and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) June 28, June 30, % Change June 28, June 30, % Change United States $ 5,402 $ 6,335 (15 ) $ 11,053 $ 12,510 (12 ) Developed Europe (a) 2,088 2,228 (6 ) 4,009 4,315 (7 ) Developed Rest of World (b) 1,552 1,639 (5 ) 3,008 3,174 (5 ) Emerging Markets (c) 2,759 3,062 (10 ) 5,759 6,383 (10 ) Revenues $ 11,801 $ 13,264 (11 ) $ 23,829 $ 26,382 (10 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019 , and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information for several of our major products: (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATION OR CLASS June 28, June 30, June 28, June 30, TOTAL REVENUES $ 11,801 $ 13,264 $ 23,829 $ 26,382 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) $ 9,795 $ 9,432 $ 19,802 $ 18,477 Internal Medicine (a) $ 2,279 $ 2,243 $ 4,610 $ 4,380 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,272 1,085 2,572 2,096 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 235 276 505 549 Premarin family Symptoms of menopause 152 193 304 361 BMP2 Development of bone and cartilage 57 79 127 145 Toviaz Overactive bladder 64 65 124 125 All other Internal Medicine Various 498 544 978 1,103 Oncology $ 2,647 $ 2,236 $ 5,082 $ 4,198 Ibrance Metastatic breast cancer 1,349 1,261 2,598 2,394 Xtandi alliance revenues Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer 266 201 475 369 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 209 248 414 480 Inlyta Advanced RCC 195 104 364 177 Xalkori ALK-positive and ROS1-positive advanced NSCLC 138 133 287 255 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 113 97 213 177 Retacrit (b) Anemia 87 51 176 82 Braftovi In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy 36 — 74 — Mektovi In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation 32 — 69 — All other Oncology Various 221 140 412 262 Hospital (a), (c) $ 1,794 $ 1,838 $ 3,807 $ 3,665 Sulperazon Bacterial infections 102 165 289 342 Medrol Anti-inflammatory glucocorticoid 78 120 207 240 Zithromax Bacterial infections 55 73 193 177 Precedex Sedation agent in surgery or intensive care 114 40 156 80 Vfend Fungal infections 75 94 149 178 Panzyga Primary humoral immunodeficiency 63 44 136 61 (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATION OR CLASS June 28, June 30, June 28, June 30, Zyvox Bacterial infections 55 71 125 134 Fragmin Treatment/prevention of venous thromboembolism 58 63 118 123 Pfizer CentreOne (d) Various 224 204 376 380 All other Anti-infectives Various 367 420 811 825 All other Hospital (c) Various 603 544 1,245 1,124 Vaccines $ 1,247 $ 1,375 $ 2,857 $ 2,988 Prevnar 13/Prevenar 13 Pneumococcal disease 1,116 1,179 2,566 2,665 Nimenrix Meningococcal disease 56 58 130 107 All other Vaccines Various 75 138 161 215 Inflammation & Immunology (I&I) $ 1,149 $ 1,219 $ 2,127 $ 2,256 Xeljanz RA, PsA, UC 635 613 1,086 1,036 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 337 420 684 871 Inflectra/Remsima (b) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 150 153 308 291 All other I&I Various 26 34 48 59 Rare Disease $ 681 $ 521 $ 1,319 $ 991 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 277 63 508 104 BeneFIX Hemophilia B 109 121 230 247 Genotropin Replacement of human growth hormone 106 125 209 232 Refacto AF/Xyntha Hemophilia A 91 108 181 214 Somavert Acromegaly 67 68 131 128 All other Rare Disease Various 31 35 61 66 UPJOHN (a) $ 2,006 $ 2,970 $ 4,027 $ 6,184 Lipitor Reduction of LDL cholesterol 431 407 836 1,029 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 349 1,175 706 2,362 Norvasc Hypertension 222 216 419 516 Celebrex Arthritis pain and inflammation, acute pain 139 174 295 347 Viagra Erectile dysfunction 94 114 222 259 Effexor Depression and certain anxiety disorders 86 86 163 163 Zoloft Depression and certain anxiety disorders 79 73 157 143 EpiPen (a) Epinephrine injection used in treatment of life-threatening allergic reactions 64 67 136 123 Xalatan/Xalacom Glaucoma and ocular hypertension 65 72 126 133 All other Upjohn Various 476 587 968 1,109 CONSUMER HEALTHCARE BUSINESS (e) $ — $ 862 $ — $ 1,721 Total Alliance revenues $ 1,404 $ 1,187 $ 2,786 $ 2,277 Total Biosimilars (b) $ 289 $ 217 $ 578 $ 396 Total Sterile Injectable Pharmaceuticals (f) $ 1,237 $ 1,218 $ 2,644 $ 2,455 (a) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation. (b) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (c) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (d) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements. (e) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B . (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details) $ in Millions	7 Months Ended
	Jul. 31, 2019Operating_Segment	Jun. 28, 2020USD ($)	Jan. 01, 2020Accounting_standard	Dec. 31, 2019USD ($)	Jan. 01, 2019Accounting_standard
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments | Operating_Segment	3
Number of accounting standards adopted | Accounting_standard			4		4
Accrued rebates and other accruals | $		$ 5,512		$ 5,689

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 31, 2019
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 5,512	$ 5,689
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,129	1,257
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,210	3,285
Other accruals	576	581
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 598	$ 565

Acquisition, Equity-Method In_3

Acquisition, Equity-Method Investment and Licensing Arrangements - Array BioPharma (Details) - Array [Member] $ / shares in Units, $ in Billions	Jul. 30, 2019USD ($)$ / shares
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares	$ 48
Payments for acquisition, cash portion	$ 11.2
Acquisition of business, net of cash acquired	$ 10.9

Acquisition, Equity-Method In_4

Acquisition, Equity-Method Investment and Licensing Arrangements - Equity Method Investment Narrative (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended			6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020	Sep. 29, 2019	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Dec. 31, 2019	Jul. 31, 2019
Schedule of Equity Method Investments [Line Items]
Gain on completion of Consumer Healthcare JV transaction	[1]		$ 0		$ 0	$ 6	$ 0
Equity-method investments	[2]	$ 15,578	15,578			15,578		$ 17,133
GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage									32.00%
Gain on completion of Consumer Healthcare JV transaction				$ 8,100
Gain on completion of Consumer Healthcare JV transaction, after-tax				$ 5,400
Equity-method investments		15,400	15,400			15,400		17,000
Equity method investment earnings			129			140
Fair value of equity method investment									$ 15,700
Underlying equity in net assets								11,000	11,200
Difference between carrying amount and underlying equity								$ 4,800	$ 4,500
Decrease due to foreign currency translation						1,100
Dividend received		$ 519
GSK [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage									68.00%
OID [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization			$ 4			$ 48
Consumer Healthcare [Member] | Held-for-sale [Member]
Schedule of Equity Method Investments [Line Items]
Pre-tax income attributable to disposal group					$ 274		$ 554
Minimum [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period						6 years
Maximum [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period						20 years
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisition, Equity-Method In_5

Acquisition, Equity-Method Investment and Licensing Arrangements - Schedule of Equity-Method Investment (Details) - USD ($) $ in Millions		3 Months Ended				6 Months Ended
		Jun. 28, 2020		Mar. 31, 2020	Jun. 30, 2019	Jun. 28, 2020		Mar. 31, 2020	Jun. 30, 2019	Mar. 29, 2020	Dec. 31, 2019		Mar. 31, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Current assets	[1]	$ 46,424				$ 46,424					$ 32,803
Total assets	[1]	177,934				177,934					167,489
Current liabilities	[1]	32,723				32,723					37,304
Total liabilities	[1]	113,370				113,370					104,042
Equity attributable to shareholders	[1]	64,336				64,336					63,143
Equity attributable to noncontrolling interests	[1]	228				228					303
Total equity	[2]	64,564	[1]		$ 59,924	64,564	[1]		$ 59,924	$ 65,338	$ 63,447	[1]	$ 59,158	$ 63,758
Income from continuing operations	[3]	3,434			5,056	6,845			8,945
Net income before allocation to noncontrolling interests	[2],[3],[4],[5]	3,434			5,056	6,845			8,945
Income attributable to shareholders	[3]	$ 3,426			$ 5,046	$ 6,828			$ 8,929
GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Current assets				$ 8,213				$ 8,213
Noncurrent assets				37,627				37,627
Total assets				45,840				45,840
Current liabilities				5,524				5,524
Noncurrent liabilities				5,152				5,152
Total liabilities				10,677				10,677
Equity attributable to shareholders				35,031				35,031
Equity attributable to noncontrolling interests				133				133
Total equity				35,163				35,163
Net sales				3,503				6,691
Cost of sales				(1,394)				(3,205)
Gross profit				2,109				3,486
Income from continuing operations				425				471
Net income before allocation to noncontrolling interests				425				471
Income attributable to shareholders				$ 405				$ 441
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.

Acquisition, Equity-Method In_6

Acquisition, Equity-Method Investment and Licensing Arrangements - Valneva SE (Details) - Licensing Agreements [Member] - Valneva SE [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 28, 2020	Jun. 28, 2020	Apr. 30, 2020
Business Acquisition [Line Items]
Maximum potential cash payments			$ 308
Potential development milestones			35
Potential early commercialization milestones			$ 143
Valneva's development cost ownership percentage		30.00%
Research and Development Expense [Member]
Business Acquisition [Line Items]
Upfront payment for licensing arrangement	$ 130

Acquisition, Equity-Method In_7

Acquisition, Equity-Method Investment and Licensing Arrangements - BioNTech SE (Details) - Licensing Agreements [Member] - BioNTech SE [Member] - USD ($) $ in Millions	Apr. 09, 2020	Jul. 31, 2020	Jun. 28, 2020
Business Acquisition [Line Items]
Value of shares purchased			$ 113
Potential future milestone payments	$ 563
Maximum potential cash payments	$ 748
Research and development arrangement, percentage of costs to be reimbursed	50.00%
Research and Development Expense [Member]
Business Acquisition [Line Items]
Upfront payment for licensing arrangement			$ 72
Subsequent Event [Member]
Business Acquisition [Line Items]
Value of shares purchased		$ 50

Restructuring Charges and Oth_3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($) $ in Millions	6 Months Ended		9 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred		$ 32
Focused Company Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 1,200		$ 1,200
Restructuring costs incurred	566		549
2017-2019 Initiatives and Organizing for Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred		180
Manufacturing Cost Reduction [Member] | Focused Company Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 400		$ 400
Percentage of expected costs to be non-cash	20.00%
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred		(199)
Business Integration Costs [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred		$ 51

Restructuring Charges and Oth_4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Restructuring charges:
Employee terminations		$ 346	$ (166)	$ 371	$ (167)
Asset impairments		(8)	(9)	23	0
Exit costs		1	31	1	34
Restructuring charges/(credits)	[1]	340	(144)	396	(134)
Transaction costs	[2]	11	0	14	0
Integration costs and other	[3]	11	29	21	64
Restructuring charges and certain acquisition-related costs	[4]	362	(115)	431	(69)
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	6	10	6	23
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	75	42	99	69
Total costs associated with acquisitions and cost-reduction/productivity initiatives		449	(59)	566	32
Other (income)/deductions––net [Member]
Restructuring charges:
Net periodic benefit costs recorded in Other (income)/deductions––net		5	4	29	10
Cost of sales [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	4	7	10	15
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	11	17	21	31
Selling, informational and administrative expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	0	1	0	2
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	63	16	78	25
Research and development expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	2	2	(3)	5
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	$ 1	$ 9	$ 1	$ 13
[1]	In the second quarter and first six months of 2020 , restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the second quarter and first six months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report. The restructuring activities for 2020 are associated with the following: • For the second quarter of 2020 , Biopharma ( $12 million credit); Upjohn ( $1 million credit); and Other ( $352 million charge). • For the first six months of 2020 , Biopharma ( $9 million credit); Upjohn ( $12 million charge); and Other ( $393 million charge). The restructuring activities for 2019 are associated with the following: • For the second quarter of 2019 , Biopharma ( $62 million credit); Upjohn ( $9 million credit); and Other ( $74 million credit). • For the first six months of 2019 , Biopharma ( $48 million credit); Upjohn ( $22 million credit); and Other ( $63 million credit). Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the second quarter and first six months of 2020 , restructuring costs identified as Other primarily relate to corporate enabling functions.
[2]	Transaction costs represent external costs for banking, legal, accounting and other similar services.
[3]	Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the second quarter and first six months of 2020 , integration costs and other were mostly related to our acquisition of Array. In the second quarter and first six months of 2019 , integration costs and other were primarily related to our acquisition of Hospira.
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth_5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)	[1]	$ 340	$ (144)	$ 396	$ (134)
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		352	(74)	393	(63)
Biopharma [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		(12)	(62)	(9)	(48)
Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		$ (1)	$ (9)	$ 12	$ (22)
[1]	In the second quarter and first six months of 2020 , restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the second quarter and first six months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report. The restructuring activities for 2020 are associated with the following: • For the second quarter of 2020 , Biopharma ( $12 million credit); Upjohn ( $1 million credit); and Other ( $352 million charge). • For the first six months of 2020 , Biopharma ( $9 million credit); Upjohn ( $12 million charge); and Other ( $393 million charge). The restructuring activities for 2019 are associated with the following: • For the second quarter of 2019 , Biopharma ( $62 million credit); Upjohn ( $9 million credit); and Other ( $74 million credit). • For the first six months of 2019 , Biopharma ( $48 million credit); Upjohn ( $22 million credit); and Other ( $63 million credit). Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the second quarter and first six months of 2020 , restructuring costs identified as Other primarily relate to corporate enabling functions.

Restructuring Charges and Oth_6

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]			$ 933
Provision	[2]	$ 340	$ (144)	396	$ (134)
Utilization and other	[3]			(378)
Balance, June 28, 2020	[4]	951		951
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]			887
Provision				371
Utilization and other	[3]			(341)
Balance, June 28, 2020	[4]	918		918
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]			0
Provision				23
Utilization and other	[3]			(23)
Balance, June 28, 2020	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]			46
Provision				1
Utilization and other	[3]			(14)
Balance, June 28, 2020	[4]	$ 34		$ 34
[1]	Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ).
[2]	In the second quarter and first six months of 2020 , restructuring charges mainly represent employee termination costs associated with our Transforming to a More Focused Company cost reduction program. In the second quarter and first six months of 2019 , restructuring credits mostly represent the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes to Consolidated Financial Statements–– Note 5D. Tax Matters: Tax Contingencies in our 2019 Financial Report. The restructuring activities for 2020 are associated with the following: • For the second quarter of 2020 , Biopharma ( $12 million credit); Upjohn ( $1 million credit); and Other ( $352 million charge). • For the first six months of 2020 , Biopharma ( $9 million credit); Upjohn ( $12 million charge); and Other ( $393 million charge). The restructuring activities for 2019 are associated with the following: • For the second quarter of 2019 , Biopharma ( $62 million credit); Upjohn ( $9 million credit); and Other ( $74 million credit). • For the first six months of 2019 , Biopharma ( $48 million credit); Upjohn ( $22 million credit); and Other ( $63 million credit). Restructuring costs identified as Other are for restructuring activities associated with corporate enabling functions, WRDM, GPD and other manufacturing and commercial operations, as applicable. For the second quarter and first six months of 2020 , restructuring costs identified as Other primarily relate to corporate enabling functions.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ( $625 million ) and Other noncurrent liabilities ( $326 million ).

Restructuring Charges and Oth_7

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Jun. 28, 2020		Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 951	[1]	$ 933	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	625		714
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 326		$ 219
[1]	Included in Other current liabilities ( $625 million ) and Other noncurrent liabilities ( $326 million ).
[2]	Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ).

Other (Income)_Deductions - N_3

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Other Income and Expenses [Abstract]
Interest income	[1]	$ (19)	$ (59)	$ (53)	$ (125)
Interest expense	[1]	372	389	762	750
Net interest expense		353	330	709	625
Royalty-related income	[2]	(191)	(231)	(311)	(320)
Net (gains)/losses on asset disposals		1	0	2	(1)
Net gains recognized during the period on equity securities	[3],[4]	(732)	(36)	(478)	(147)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[5]	(100)	(22)	(215)	(104)
Net periodic benefit credits other than service costs	[6]	(108)	(51)	(175)	(91)
Certain legal matters, net		17	15	26	19
Certain asset impairments	[7]	0	10	0	160
Business and legal entity alignment costs	[8]	0	137	0	256
Net losses on early retirement of debt		0	0	0	138
GSK Consumer Healthcare JV equity method (income)/loss	[9]	(126)	0	(92)	0
Other, net	[10]	25	(27)	(107)	(318)
Other (income)/deductions––net	[11]	$ (862)	$ 126	$ (641)	$ 218
[1]	Interest income decreased in the second quarter and first six months of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense decreased in the second quarter of 2020 mainly as a result of the retirement of higher-coupon debt and the issuance of new debt with a lower coupon than the debt outstanding for the comparative prior year period. Interest expense increased in the first six months of 2020
[2]	Royalty-related income for the second quarter and first six months of 2019 included a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million .
[3]	The gains in the second quarter of 2020 include, among other things, unrealized gains of $508 million related to our investment in Allogene and unrealized gains of $61 million related to our investment in BioNTech. The gains in the first six months of 2020 include, among other things, unrealized gains of $374 million related to our investment in Allogene and unrealized gains of $127 million related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of $104 million related to our investment in Cortexyme, Inc. For additional information on investments, see Note 7B .
[4]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[5]	Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter and first six months of 2020 , mainly includes, among other things, $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, and $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC. The first six months of 2020 also includes an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first six months of 2019 , primarily included $68 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® .
[6]	For additional information, see Note 10 .
[7]	The first six months of 2019 included intangible asset impairment charges of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development, (ii) $40 million related to an Upjohn finite-lived developed technology right, acquired in connection with our acquisition of King, for government defense products and reflected, among other things, updated commercial forecasts including manufacturing cost assumptions, and (iii) $10 million related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only, associated with Biopharma and reflected , among other things, updated commercial forecasts. In addition, the first six months of 2019 included other asset impairments of $20 million .
[8]	In the second quarter and first six months of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.
[9]	Includes our share of the GSK Consumer Healthcare joint venture’s earnings and the amortization of basis differences, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture. See Note 2B for additional information.
[10]	The second quarter of 2020 includes, among other things, dividend income of $76 million from our investment in ViiV, and charges of $86 million , reflecting the change in the fair value of contingent consideration. The first six months of 2020 includes, among other things, dividend income of $153 million from our investment in ViiV and charges of $99 million , reflecting the change in the fair value of contingent consideration. The second quarter of 2019 included, among other things, charges of $81 million , reflecting the change in the fair value of contingent consideration, dividend income of $76 million from our investment in ViiV, and $25 million of income from insurance recoveries related to Hurricane Maria. The first six months of 2019 included, among other things, dividend income of $140 million from our investment in ViiV and $50 million of income from insurance recoveries related to Hurricane Maria.
[11]	Amounts may not add due to rounding.

Other (Income)_Deductions - N_4

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Loss Contingencies [Line Items]
Proceeds from legal dispute			$ 82		$ 82
Unrealized gain (loss) on equity securities	[1]	$ 733	31	$ 459	137
Other asset impairments					20
Insurance Recoveries			(25)		(50)
Change in fair value of contingent consideration			81
Allogene [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		508		374
BioNTech SE [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		61		127
Cortexyme, Inc. [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities					104
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income		76	$ 76	153	140
Puma Technologies [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received		40		40
Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received		30		30
Mylan [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received					68
Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]
Loss Contingencies [Line Items]
Consideration transferred		75		75
Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member] | King [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge					40
Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member] | Anacor [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge					10
Gene Therapies [Member] | WRDM [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge					$ 90
ViiV [Member]
Loss Contingencies [Line Items]
Change in fair value of contingent consideration		$ 86		$ 99
[1]	Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $67 million and upward adjustments of $66 million . Impairments, downward and upward adjustments were not significant in the second quarter and the first six months of 2020 and 2019 .

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Millions	Apr. 01, 2021	Jul. 31, 2020	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Income Taxes [Line Items]
Effective tax rate for income from continuing operations			13.10%	(22.10%)	12.70%	(5.70%)
Tax benefit due to settlement				$ 1,400
Repatriation tax liability			$ 15,000		$ 15,000
Income Taxes Payable [Member]
Income Taxes [Line Items]
Repatriation tax liability			$ 1,400		$ 1,400
Subsequent Event [Member]
Income Taxes [Line Items]
Installment payments for repatriation tax		$ 680
Subsequent Event [Member] | Forecast [Member]
Income Taxes [Line Items]
Installment payments for repatriation tax	$ 750

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Foreign currency translation adjustments, net	[1]	$ 60	$ (17)	$ (192)	$ 10
Unrealized holding gains/(losses) on derivative financial instruments, net		51	(53)	(82)	6
Reclassification adjustments for gains included in net income		(35)	(4)	(20)	(59)
Derivatives qualifying as hedges, tax, total		16	(57)	(102)	(53)
Unrealized holding gains/(losses) on available-for-sale securities, net		5	(1)	(1)	4
Reclassification adjustments for losses included in net income		6	3	7	5
Available-for-sale securities, tax, total		11	2	6	9
Benefit plans: actuarial gains/(losses), net		2	(1)	(19)	(1)
Reclassification adjustments related to amortization		16	15	31	18
Reclassification adjustments related to settlements, net		2	0	12	1
Other		16	8	20	3
Defined benefit plans, actuarial gain (loss), tax, total		35	23	43	21
Reclassification adjustments related to amortization of prior service costs and other, net		(11)	(11)	(21)	(22)
Other		1	0	1	0
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(9)	(11)	(20)	(22)
Tax provision/(benefit) on other comprehensive loss	[2]	$ 113	$ (59)	$ (265)	$ (34)
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	[1]		$ 63,143
Balance, June 28, 2020	[1]	$ 64,336	64,336
Foreign currency translation income (loss) attributable to noncontrolling interest			12
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			(11,640)
Other comprehensive income/(loss)	[2]		(1,605)
Balance, June 28, 2020		(13,246)	(13,246)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			(5,952)
Other comprehensive income/(loss)	[2]		(1,310)
Balance, June 28, 2020		(7,262)	(7,262)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			20
Other comprehensive income/(loss)	[2]		(353)
Balance, June 28, 2020		(333)	(333)
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			(35)
Other comprehensive income/(loss)	[2]		44
Balance, June 28, 2020		9	9
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			(6,257)
Other comprehensive income/(loss)	[2]		79
Balance, June 28, 2020		(6,178)	(6,178)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019			584
Other comprehensive income/(loss)	[2]		(65)
Balance, June 28, 2020		518	518
GSK Consumer Healthcare [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax		$ 291	$ (902)
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $12 million loss for the first six months of 2020. Includes after-tax losses of approximately $902 million related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), and losses from the weakening of certain major currencies against the U.S. dollar. These losses were partially offset by the results of our net investment hedging program.

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[1]	$ 13,033	$ 705
Total other noncurrent assets	[2]	4,327	4,450
Total assets	[2]	177,934	167,489
Total liabilities		993	718
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		24,402	11,176
Total liabilities		993	718
Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		7,672	6,687
Total short-term investments		20,705	7,392
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		431	465
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		17	53
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		413	413
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	2,072	1,902
Available-for-sale debt securities		254	315
Total long-term investments		2,326	2,216
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		362	526
Insurance contracts	[4]	578	575
Total other noncurrent assets		940	1,102
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		140	266
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		221	261
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		127	114
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		127	114
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		866	604
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		866	604
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		2,046	1,863
Total liabilities		0	0
Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Total short-term investments		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	2,046	1,863
Available-for-sale debt securities		0	0
Total long-term investments		2,046	1,863
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Insurance contracts	[4]	0	0
Total other noncurrent assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		22,355	9,313
Total liabilities		993	718
Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		7,672	6,687
Total short-term investments		20,705	7,392
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		431	465
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		17	53
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		413	413
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[3]	26	39
Available-for-sale debt securities		254	315
Total long-term investments		280	354
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		362	526
Insurance contracts	[4]	578	575
Total other noncurrent assets		940	1,102
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		140	266
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		221	261
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		127	114
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		127	114
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		866	604
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		866	604
Money market funds [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[5]	13,033	705
Money market funds [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[5]	0	0
Money market funds [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[5]	13,033	705
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		6,218	4,863
Government and agency - non U.S. [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		6,218	4,863
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		6,218	4,863
Government and agency - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		257	1,114
Government and agency - U.S. [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		14	811
Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		243	303
Government and agency - U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		14	811
Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		243	303
Corporate and other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[6]	1,451	1,025
Corporate and other [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,440	1,013
Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		11	11
Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,440	1,013
Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 11	$ 11
[1]	As of June 28, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.
[2]	Amounts may not add due to rounding.
[3]	As of June 28, 2020 , long-term equity securities of $163 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.
[4]	Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the condensed consolidated statements of income (see Note 4 ).
[5]	As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.
[6]	Primarily issued by a diverse group of corporations.

Financial Instruments - Finan_2

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020	Jun. 30, 2019	Dec. 31, 2019
Footnotes to selected financial assets and liabilities:
Proceeds from issuance of long-term debt	[1],[2]		$ 16,606	$ 4,942
Recurring [Member]
Footnotes to selected financial assets and liabilities:
Long-term equity securities held in trust		$ 163	163		$ 176
Subsidiaries [Member] | Upjohn Inc [Member]
Footnotes to selected financial assets and liabilities:
Proceeds from issuance of long-term debt		$ 11,400	$ 11,400
[1]	Amounts may not add due to rounding.
[2]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).

Financial Instruments - Finan_3

Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion(a)	[1]	$ 50,529	$ 35,955
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion(a)	[1]	59,121	40,842
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion(a)	[1]	$ 59,121	$ 40,842
[1]	As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.

Financial Instruments - Total S

Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Short-term investments
Equity securities with readily determinable fair value	[1]	$ 13,033	$ 705
Available-for-sale debt securities		7,672	6,687
Held-to-maturity debt securities		288	1,133
Total Short-term investments		20,993	8,525
Long-term investments
Equity securities with readily determinable fair values		2,072	1,902
Available-for-sale debt securities		254	315
Held-to-maturity debt securities		43	42
Private equity securities at cost		772	756
Total Long-term investments	[2]	3,142	3,014
Equity-method investments	[2]	15,578	17,133
Total long-term investments and equity-method investments		18,720	20,147
Held-to-maturity cash equivalents		$ 119	$ 163
[1]	As of June 28, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions (see Note 7D ) are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.
[2]	Amounts may not add due to rounding.

Financial Instruments - Total_2

Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020	Jun. 30, 2019
Debt Securities, Available-for-sale [Line Items]
Proceeds from issuance of long-term debt	[1],[2]		$ 16,606	$ 4,942
Subsidiaries [Member] | Upjohn Inc [Member]
Debt Securities, Available-for-sale [Line Items]
Proceeds from issuance of long-term debt		$ 11,400	$ 11,400
[1]	Amounts may not add due to rounding.
[2]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost		$ 8,366	$ 8,380
Debt securities, gross unrealized gains		16	6
Debt securities, gross unrealized losses		(5)	(47)
Available-for-sale securities and held-to-maturity securities		8,376	8,340
Debt securities maturities, within 1 year, fair value		8,079
Debt securities maturities, over 1 to 5 years, fair value		263
Debt securities maturities, over 5 years, fair value		35
Government and agency - non U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		6,209	4,895
Available-for-sale debt securities, gross unrealized gains		12	6
Available-for-sale debt securities, gross unrealized losses		(3)	(38)
Available-for-sale debt securities, fair value		6,218	4,863
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		6,218
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		0
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		6,218	4,863
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		222	803
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		222	803
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		218
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		4
Held-to-maturity securities, debt maturities, total		222	803
Government and agency - U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		257	1,120
Available-for-sale debt securities, gross unrealized gains		1	0
Available-for-sale debt securities, gross unrealized losses		(1)	(6)
Available-for-sale debt securities, fair value		257	1,114
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		14
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		243
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		257	1,114
Corporate and other [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	[1]	1,450	1,027
Available-for-sale debt securities, gross unrealized gains	[1]	2	0
Available-for-sale debt securities, gross unrealized losses	[1]	(1)	(2)
Available-for-sale debt securities, fair value	[1]	1,451	1,025
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[1]	1,440
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[1]	11
Available-for-sale securities, debt maturities, over 5 years, fair value	[1]	0
Available-for-sale debt securities, fair value	[1]	1,451	1,025
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		228	535
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		228	535
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		189
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		9
Held-to-maturity securities, debt maturities, over 5 years, fair value		30
Held-to-maturity securities, debt maturities, total		$ 228	$ 535
[1]	Primarily issued by a diverse group of corporations.

Financial Instruments - Inves_2

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Financial Instruments [Abstract]
Net gains recognized during the period on investments in equity securities	[1],[2]	$ (732)	$ (36)	$ (478)	$ (147)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period		1	(6)	(18)	(10)
Net unrealized gains during the reporting period on equity securities still held at the reporting date	[3]	$ (733)	$ (31)	$ (459)	$ (137)
[1]	The gains in the second quarter of 2020 include, among other things, unrealized gains of $508 million related to our investment in Allogene and unrealized gains of $61 million related to our investment in BioNTech. The gains in the first six months of 2020 include, among other things, unrealized gains of $374 million related to our investment in Allogene and unrealized gains of $127 million related to our investment in BioNTech. The gains in the first six months of 2019 included, among other things, unrealized gains of $104 million related to our investment in Cortexyme, Inc. For additional information on investments, see Note 7B .
[2]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[3]	Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $67 million and upward adjustments of $66 million . Impairments, downward and upward adjustments were not significant in the second quarter and the first six months of 2020 and 2019 .

Financial Instruments Financial

Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) $ in Millions	Jun. 28, 2020USD ($)
Financial Instruments [Abstract]
Cumulative impairment losses and downward price adjustments on equity securities	$ 67
Cumulative upward price adjustments on equity securities	$ 66

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Financial Instruments [Abstract]
Commercial paper		$ 10,660	$ 13,915
Current portion of long-term debt, principal amount		1,481	1,458
Other short-term borrowings, principal amount	[1]	956	860
Total short-term borrowings, principal amount		13,097	16,233
Net fair value adjustments related to hedging and purchase accounting		1	5
Net unamortized discounts, premiums and debt issuance costs		(14)	(43)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[2]	$ 13,084	$ 16,195
[1]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E .
[2]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt - New Issuances (Details) € in Millions, $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020USD ($)	Jun. 28, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 28, 2020EUR (€)
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt	[1],[2]		$ 16,606	$ 4,942
Senior Notes [Member]
Debt Instrument [Line Items]
Effective interest rate		2.67%	2.67%		2.67%
Senior Notes [Member] | 2.625% notes [Member]
Debt Instrument [Line Items]
Principal	[3]	$ 1,250	$ 1,250
Stated interest rate		2.625%	2.625%		2.625%
Senior Notes [Member] | Long Term Debt Issued First Quarter 2020 [Member]
Debt Instrument [Line Items]
Principal	[4]	$ 1,250	$ 1,250
Parent [Member]
Debt Instrument [Line Items]
Principal		$ 4,000	$ 4,000
Effective interest rate		2.11%	2.11%		2.11%
Parent [Member] | Senior Notes [Member] | 0.800% notes [Member]
Debt Instrument [Line Items]
Principal		$ 750	$ 750
Stated interest rate		0.80%	0.80%		0.80%
Parent [Member] | Senior Notes [Member] | 1.700% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,000	$ 1,000
Stated interest rate		1.70%	1.70%		1.70%
Parent [Member] | Senior Notes [Member] | 2.550% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,000	$ 1,000
Stated interest rate		2.55%	2.55%		2.55%
Parent [Member] | Senior Notes [Member] | 2.700% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,250	$ 1,250
Stated interest rate		2.70%	2.70%		2.70%
Subsidiaries [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Redemption price percentage			101.00%
Upjohn Inc [Member] | Subsidiaries [Member]
Debt Instrument [Line Items]
Principal		$ 7,450	$ 7,450
Effective interest rate		2.95%	2.95%		2.95%
Proceeds from issuance of long-term debt		$ 11,400	$ 11,400
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.125% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,000	$ 1,000
Stated interest rate		1.125%	1.125%		1.125%
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.650% notes [Member]
Debt Instrument [Line Items]
Principal		$ 750	$ 750
Stated interest rate		1.65%	1.65%		1.65%
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 2.300% notes [Member]
Debt Instrument [Line Items]
Principal		$ 750	$ 750
Stated interest rate		2.30%	2.30%		2.30%
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 2.700% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,450	$ 1,450
Stated interest rate		2.70%	2.70%		2.70%
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 3.850% notes [Member]
Debt Instrument [Line Items]
Principal		$ 1,500	$ 1,500
Stated interest rate		3.85%	3.85%		3.85%
Upjohn Inc [Member] | Subsidiaries [Member] | Senior Notes [Member] | 4.000% notes [Member]
Debt Instrument [Line Items]
Principal		$ 2,000	$ 2,000
Stated interest rate		4.00%	4.00%		4.00%
Upjohn Finance B.V. [Member] | Subsidiaries [Member]
Debt Instrument [Line Items]
Principal | €					€ 3,600
Effective interest rate		1.37%	1.37%		1.37%
Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 0.816% notes [Member]
Debt Instrument [Line Items]
Principal | €					€ 750
Stated interest rate		0.816%	0.816%		0.816%
Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.023% notes [Member]
Debt Instrument [Line Items]
Principal | €					€ 750
Stated interest rate		1.023%	1.023%		1.023%
Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.362% notes [Member]
Debt Instrument [Line Items]
Principal | €					€ 850
Stated interest rate		1.362%	1.362%		1.362%
Upjohn Finance B.V. [Member] | Subsidiaries [Member] | Senior Notes [Member] | 1.908% notes [Member]
Debt Instrument [Line Items]
Principal | €					€ 1,250
Stated interest rate		1.908%	1.908%		1.908%
[1]	Amounts may not add due to rounding.
[2]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).
[3]	The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.
[4]	The effective interest rate for the notes at issuance was 2.67% .

Financial Instruments - Long-_2

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jun. 28, 2020	Jun. 28, 2020	Jun. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting		$ 1	$ 1		$ 5
Net unamortized discounts, premiums and debt issuance costs		(14)	(14)		(43)
Total long-term debt, carried at historical proceeds, as adjusted	[1],[2]	50,529	50,529		35,955
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)	[1]	1,481	1,481		1,462
Proceeds from issuance of long-term debt	[3],[4]		16,606	$ 4,942
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount	[5]	49,187	49,187		34,820
Net fair value adjustments related to hedging and purchase accounting		1,654	1,654		1,305
Net unamortized discounts, premiums and debt issuance costs		(317)	(317)		(176)
Other long-term debt		5	5		5
Total long-term debt, carried at historical proceeds, as adjusted		50,529	50,529		35,955
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)		1,481	1,481		$ 1,462
Subsidiaries [Member] | Upjohn Inc [Member]
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt		$ 11,400	$ 11,400
[1]	Amounts may not add due to rounding.
[2]	The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see Note 7D. Financial Instruments: Long-Term Debt
[3]	Amounts may not add due to rounding.
[4]	Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt ).
[5]	As of June 28, 2020 , $11.4 billion of proceeds from the Upjohn debt transactions are invested in money market funds and included in Restricted short-term investments in the condensed consolidated balance sheet.

Financial Instruments - Long-_3

Financial Instruments - Long-Term Debt Narrative (Details) $ in Millions	Mar. 29, 2020USD ($)
Unsecured Debt [Member] | Senior Notes Due 2047 [Member]
Debt Instrument [Line Items]
Repurchase amount	$ 1,065

Financial Instruments - Deriva

Financial Instruments - Derivative Narrative (Details) $ in Millions	6 Months Ended
	Jun. 28, 2020USD ($)
Derivative [Line Items]
Derivatives in a net liability position	$ 928
Collateral posted	922
Cash collateral received	$ 858
Foreign exchange contracts [Member]
Derivative [Line Items]
Derivative term of contract	2 years

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Derivative [Line Items]
Asset		$ 792	$ 992
Liability		993	718
Derivatives designated as hedging instruments [Member]
Derivative [Line Items]
Asset		708	909
Liability		914	662
Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	22,543	25,193
Asset	[1]	551	591
Liability	[1]	914	662
Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		1,995	6,645
Asset		158	318
Liability		0	0
Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		14,433	19,623
Asset		84	82
Liability		79	55
Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 5,200	$ 5,900
[1]	The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.2 billion as of June 28, 2020 and $5.9 billion as of December 31, 2019.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1]	$ 213	$ (176)	$ (288)	$ 91
All other, net - Amount of Gains/(Losses) Recognized in OCI	[2],[3],[4]	12	0	12	1
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	56	(216)	139	188
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[5]	186	81	167	343
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	8	(4)	(51)	(124)
Other (Income) Deductions And Cost Of Sales [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[4]	0	0	(1)	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	228	111	251	398
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[6]	187	(204)	(341)	6
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	(144)	(48)	240	(25)
Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[7]	0	(16)	8	19
Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[7]	(42)	(27)	3	11
Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	0	0		0
Hedged item	[3]	0	0		0
Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	6	483	392	813
Hedged item	[3]	(6)	(483)	(392)	(813)
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[6]	172	48	126	257
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	0	0	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[7]	0	0	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[7]	0	0	0	0
Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	8	(4)	(51)	(124)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	13	28	42	84
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	14	32	41	86
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	29	52	176	93
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	$ 42	$ 31	$ 84	$ 55
[1]	Amounts may not add due to rounding.
[2]	For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive loss––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive loss––Foreign currency translation adjustments, net.
[3]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income .
[4]	The amounts reclassified from OCI were reclassified into OID.
[5]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales , see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[6]	The amounts reclassified from OCI into COS were: • a net gain of $80 million in the second quarter of 2020 ; • a net gain of $150 million in the first six months of 2020 ; • a net gain of $59 million in the second quarter of 2019 ; and • a net gain of $103 million in the first six months of 2019 . The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $102 million within the next 12 months into income . The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
[7]	Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of June 28, 2020 , which are used as hedging instruments in net investment hedges. The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: June 28, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Short-term investments $ 45 $ — $ — $ — $ — $ — Long-term investments — — — 45 — — Long-term debt 2,023 140 1,181 7,092 266 690

Financial Instruments - Deriv_2

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Derivative [Line Items]
Amount of (Gains)/Losses Reclassified from OCI into OID and COS	[1],[2]	$ (186)	$ (81)	$ (167)	$ (343)
Pre-tax gain expected to be reclassified within the next 12 months		102		102
Unsecured Debt [Member]
Derivative [Line Items]
Long-term debt		1,800		1,800
Foreign currency long-term debt [Member]
Derivative [Line Items]
Long-term debt		2,000		2,000
Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of (Gains)/Losses Reclassified from OCI into OID and COS		$ (80)	$ (59)	$ (150)	$ (103)
[1]	Amounts may not add due to rounding.
[2]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales , see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Short-term investments [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Assets	[1]	$ 45	$ 0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset		0	0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset		0	0
Long-term investments [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Assets	[1]	0	45
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset		0	0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset		0	0
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	2,023	7,092
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		140	266
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		$ 1,181	$ 690
[1]	Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Billions	6 Months Ended
	Jun. 28, 2020USD ($)
Bank sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 1.9

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods		$ 3,002	$ 2,750
Work-in-process		4,810	4,743
Raw materials and supplies		752	790
Inventories	[1],[2]	8,564	8,283
Noncurrent inventories not included above	[3]	$ 962	$ 714
[1]	The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, network strategy and market demand, partially offset by a decrease due to foreign exchange.
[2]	Amounts may not add due to rounding.
[3]	Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_3

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Jun. 28, 2020	Dec. 31, 2019
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 7,032	$ 8,983
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		93,176	91,425
Finite-lived intangible assets, accumulated amortization	[1]	(66,667)	(65,037)
Finite-lived intangible assets, net		26,509	26,387
Intangible assets, gross carrying amount	[1]	100,208	100,408
Finite-lived intangible assets, accumulated amortization	[1]	(66,667)	(65,037)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	33,541	35,370
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		1,991	1,991
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[3]	4,518	5,919
License Agreements and Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[4]	523	1,073
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[3]	89,927	88,730
Finite-lived intangible assets, accumulated amortization	[3]	(64,683)	(63,106)
Finite-lived intangible assets, net	[3]	25,244	25,625
Finite-lived intangible assets, accumulated amortization	[3]	(64,683)	(63,106)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		922	922
Finite-lived intangible assets, accumulated amortization		(757)	(741)
Finite-lived intangible assets, net		165	181
Finite-lived intangible assets, accumulated amortization		(757)	(741)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[4]	2,327	1,772
Finite-lived intangible assets, accumulated amortization	[4]	(1,226)	(1,191)
Finite-lived intangible assets, net	[4]	1,101	582
Finite-lived intangible assets, accumulated amortization	[4]	$ (1,226)	$ (1,191)
[1]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
[2]	Amounts may not add due to rounding.
[3]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy.
[4]	The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.

Identifiable Intangible Asset_4

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets Footnotes (Details) $ in Millions	6 Months Ended
	Jun. 28, 2020USD ($)
Braftovi [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)	$ 1,400
Array [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)	550
In Process Research and Development [Member] | Braftovi [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)	(1,400)
License Agreements and Other [Member] | Array [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)	$ (550)

Identifiable Intangible Asset_5

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Jun. 28, 2020
Operating Segments [Member] | Developed Technology Rights [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	99.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
Operating Segments [Member] | Brands [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Operating Segments [Member] | Brands [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	99.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
WRDM [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%

Identifiable Intangible Asset_6

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Jun. 28, 2020
Biopharma [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	42.00%
Biopharma [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	94.00%
Biopharma [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Upjohn [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	58.00%
Upjohn [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Upjohn [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	6.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset_7

Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 917	$ 1,200	$ 1,800	$ 2,400

Identifiable Intangible Asset_8

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	6 Months Ended
	Jun. 28, 2020USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2019	$ 58,653	[1]
Other	(204)	[2]
Balance, June 28, 2020	58,449	[1]
Operating Segments [Member] | Biopharma [Member]
Goodwill [Roll Forward]
Balance, December 31, 2019	48,202
Other	(155)	[2]
Balance, June 28, 2020	48,047
Operating Segments [Member] | Upjohn [Member]
Goodwill [Roll Forward]
Balance, December 31, 2019	10,451
Other	(49)	[2]
Balance, June 28, 2020	$ 10,401
[1]	Amounts may not add due to rounding.
[2]	Primarily represents the impact of foreign exchange.

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	131	157	262	315
Expected return on plan assets	(251)	(223)	(503)	(445)
Amortization of:
Actuarial losses	32	37	64	74
Prior service credits	(1)	(1)	(1)	(2)
Settlements	6	2	20	2
Special termination benefits	0	1	0	1
Defined benefit plan, net periodic benefit cost	(83)	(27)	(159)	(55)
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	36	31	72	63
Interest cost	40	54	82	109
Expected return on plan assets	(75)	(80)	(153)	(160)
Amortization of:
Actuarial losses	30	20	62	41
Prior service credits	(1)	(1)	(1)	(2)
Settlements	1	0	2	0
Special termination benefits	0	0	0	0
Defined benefit plan, net periodic benefit cost	32	25	63	51
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost	8	12	18	25
Expected return on plan assets	0	0	0	0
Amortization of:
Actuarial losses	4	2	7	5
Prior service credits	0	0	0	0
Settlements	6	0	44	0
Special termination benefits	1	3	2	9
Defined benefit plan, net periodic benefit cost	19	17	71	37
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	10	9	19	19
Interest cost	13	19	25	38
Expected return on plan assets	(9)	(8)	(18)	(16)
Amortization of:
Actuarial losses	0	1	0	2
Prior service credits	(43)	(45)	(86)	(89)
Settlements	0	0	0	0
Special termination benefits	0	1	0	1
Defined benefit plan, net periodic benefit cost	$ (30)	$ (23)	$ (60)	$ (46)

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans (Detail) - USD ($) $ in Millions		6 Months Ended
		Dec. 31, 2020	Jun. 28, 2020
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended June 28, 2020			$ 3
Expected contributions from our general assets during 2020	[1]		1,253
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended June 28, 2020			116
Expected contributions from our general assets during 2020	[1]		185
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended June 28, 2020			150
Expected contributions from our general assets during 2020	[1]		183
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended June 28, 2020			64
Expected contributions from our general assets during 2020	[1]		$ 137
Subsequent Event [Member] | Forecast [Member] | Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended June 28, 2020		$ 1,250
[1]	Contributions expected to be made for 2020 are inclusive of amounts contributed during the six months ended June 28, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Equity - Preferred Stock (Deta

Equity - Preferred Stock (Details)	May 04, 2020shares
Class of Stock [Line Items]
Preferred stock outstanding (in shares)	0
Common Stock [Member]
Class of Stock [Line Items]
Shares issued upon conversion of convertible preferred stock (in shares)	1,070,369

Equity - Dividends (Details)

Equity - Dividends (Details) - $ / shares	Jun. 25, 2020	Apr. 23, 2020	Dec. 13, 2019	Sep. 24, 2019	Jun. 27, 2019	Apr. 25, 2019	Dec. 14, 2018
Equity [Abstract]
Cash dividends declared per share (in dollars per share)	$ 0.38	$ 0.38	$ 0.38	$ 0.36	$ 0.36	$ 0.36	$ 0.36

Earnings Per Common Share Att_3

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
EPS Numerator––Basic
Income from continuing operations	[1]	$ 3,434	$ 5,056	$ 6,845	$ 8,945
Less: Net income attributable to noncontrolling interests		8	10	17	15
Income from continuing operations attributable to Pfizer Inc.		3,426	5,046	6,828	8,929
Less: Preferred stock dividends––net of tax		0	0	0	0
Income from continuing operations attributable to Pfizer Inc. common shareholders		3,426	5,045	6,828	8,929
Discontinued operations––net of tax	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders		3,426	5,045	6,828	8,929
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		3,426	5,046	6,828	8,929
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		0	0	0	0
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 3,426	$ 5,046	$ 6,828	$ 8,929
EPS Denominator
Weighted-average number of common shares outstanding––Basic (shares)	[1]	5,554	5,562	5,550	5,598
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock (shares)		65	110	66	112
Weighted-average number of common shares outstanding––Diluted (shares)	[1]	5,619	5,672	5,616	5,711
Anti-dilutive common stock equivalents (shares)	[2]	6	1	4	2
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Com_2

Contingencies and Certain Commitments (Patent Litigation) (Details) - Patent Infringement [Member]	1 Months Ended					3 Months Ended
	Jan. 31, 2020Patents	Mar. 31, 2019Patents	Jun. 30, 2018Patents	Oct. 31, 2017Patents	Mar. 31, 2017Patents	Apr. 30, 2017PatentsDefendant
Gain Contingencies [Line Items]
Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings				2
Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon			1
Pfizer Versus Generic Companies [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		2
Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon	3
Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon					3
Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon						3
Number of defendants | Defendant						25
Number of patents allegedly infringed upon due to expire December 2019						1

Contingencies and Certain Com_3

Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details) $ in Millions	1 Months Ended					3 Months Ended
	Jul. 31, 2020plaintiff	Oct. 31, 2018manufacturer	Sep. 30, 2018lagoon	Nov. 30, 2017class_action	Mar. 31, 2013lagoon	Jun. 28, 2020USD ($)lawsuit
Loss Contingencies [Line Items]
Number of class actions filed | class_action				2
Hormone Therapy Products [Member] | Class Action Versus Wyeth [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Settlement agreed | $						$ 200
Docetaxel [Member] | Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer		8
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon			2		2
Minimum [Member] | EpiPen [Member]
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit						1
Subsequent Event [Member] | Patent Infringement [Member] | NHS Scotland vs. Dr Reddy's [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff	14

Contingencies and Certain Com_4

Contingencies and Certain Commitments - Contingent Consideration (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Fair value of contingent consideration	$ 727	$ 711
Contingent consideration liability current	157	160
Contingent consideration liability noncurrent	$ 570	$ 551

Segment, Geographic and Other_3

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		7 Months Ended
		Jul. 31, 2019Operating_Segment	Jun. 28, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting [Abstract]
Number of segments | Operating_Segment		3
Assets | $	[1]		$ 177,934	$ 167,489
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other_4

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Earnings	[1],[2]	3,953	4,141	7,838	8,463
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		11,801	12,402	23,829	24,661
Earnings	[2]	7,818	8,044	15,738	16,206
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	862	0	1,721
Earnings	[2]	(1,530)	(1,193)	(3,019)	(2,306)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(910)	(1,178)	(1,722)	(2,217)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(21)	176	(34)	148
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[3]	0	0	0	0
Earnings	[2],[3]	(268)	(309)	(879)	(691)
Corporate and other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(1,136)	(1,399)	(2,245)	(2,676)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues		9,795	9,432	19,802	18,477
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		9,795	9,432	19,802	18,477
Earnings	[2]	6,650	6,071	13,379	11,954
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		2,006	2,970	4,027	6,184
Earnings	[2]	$ 1,168	$ 1,973	$ 2,359	$ 4,251
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019 , and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.
[3]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Segment, Geographic and Other_5

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income	$ 76	$ 76	$ 153	$ 140

Segment, Geographic and Other_6

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Percentage Change In Revenue		(11.00%)		(10.00%)
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 5,402	6,335	$ 11,053	12,510
Percentage Change In Revenue		(15.00%)		(12.00%)
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 2,088	2,228	$ 4,009	4,315
Percentage Change In Revenue	[2]	(6.00%)		(7.00%)
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,552	1,639	$ 3,008	3,174
Percentage Change In Revenue	[3]	(5.00%)		(5.00%)
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 2,759	$ 3,062	$ 5,759	$ 6,383
Percentage Change In Revenue	[4]	(10.00%)		(10.00%)
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019 , and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019 .
[3]	Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Segment, Geographic and Other_7

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	2,088	2,228	4,009	4,315
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,700	$ 1,800	$ 3,200	$ 3,500
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019 , and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019 .

Segment, Geographic and Other_8

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Revenue from External Customer [Line Items]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		11,801	13,264	23,829	26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,404	1,187	2,786	2,277
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	289	217	578	396
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,237	1,218	2,644	2,455
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		9,795	9,432	19,802	18,477
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,279	2,243	4,610	4,380
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,272	1,085	2,572	2,096
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	235	276	505	549
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	152	193	304	361
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	57	79	127	145
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	64	65	124	125
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	498	544	978	1,103
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,647	2,236	5,082	4,198
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,349	1,261	2,598	2,394
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		266	201	475	369
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		209	248	414	480
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		195	104	364	177
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		138	133	287	255
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		113	97	213	177
Oncology [Member] | Biopharma [Member] | Retacrit [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	87	51	176	82
Oncology [Member] | Biopharma [Member] | Braftovi [Member]
Revenue from External Customer [Line Items]
Revenues		36	0	74	0
Oncology [Member] | Biopharma [Member] | Mektovi [Member]
Revenue from External Customer [Line Items]
Revenues		32	0	69	0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		221	140	412	262
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	1,794	1,838	3,807	3,665
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	102	165	289	342
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	78	120	207	240
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	55	73	193	177
Hospital [Member] | Biopharma [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	114	40	156	80
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	75	94	149	178
Hospital [Member] | Biopharma [Member] | Panzyga [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	63	44	136	61
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	55	71	125	134
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	58	63	118	123
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5],[6]	224	204	376	380
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	367	420	811	825
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	603	544	1,245	1,124
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,247	1,375	2,857	2,988
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,116	1,179	2,566	2,665
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]
Revenue from External Customer [Line Items]
Revenues		56	58	130	107
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		75	138	161	215
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,149	1,219	2,127	2,256
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		635	613	1,086	1,036
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		337	420	684	871
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	150	153	308	291
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]
Revenue from External Customer [Line Items]
Revenues		26	34	48	59
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		681	521	1,319	991
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]
Revenue from External Customer [Line Items]
Revenues		277	63	508	104
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		109	121	230	247
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		106	125	209	232
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		91	108	181	214
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		67	68	131	128
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		31	35	61	66
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,006	2,970	4,027	6,184
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	431	407	836	1,029
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	349	1,175	706	2,362
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	222	216	419	516
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	139	174	295	347
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	94	114	222	259
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	86	86	163	163
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	79	73	157	143
Upjohn [Member] | Upjohn [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	64	67	136	123
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	65	72	126	133
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	476	587	968	1,109
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	$ 0	$ 862	$ 0	$ 1,721
[1]	Amounts may not add due to rounding.
[2]	Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
[3]	Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
[4]	Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
[5]	Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[6]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
[7]	On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B .